What's new: Drug products
Subscribe
For industry information about COVID-19, visit our COVID-19 Drugs and vaccines section.
Files added to the Web site are also posted here in the What's new section for three weeks. Once you have browsed through the entire site, all you need to do to keep current is make sure you visit this page more than once every three weeks.
Consult the Drug and Health Product Register regularly for Regulatory Decision Summaries for drugs.
Consult the Drug and Health Product Register regularly for Post-Authorization Activity Tables, which are added to Summary Basis of Decision documents for drugs.
COVID-19
September 2023
- Authorization of Pfizer-BioNTech Comirnaty Monovalent COVID-19 vaccine for the Omicron XBB.1.5 subvariant [2023-09-28]
- Authorization of Moderna Spikevax Monovalent COVID-19 vaccine for the Omicron XBB.1.5 subvariant [2023-09-12]
July 2023
May 2023
- Authorization of Moderna Spikevax Bivalent (BA.4/5) COVID-19 vaccine booster for 6 to 17 year olds [2023-05-18]
February 2023
- Authorization of Moderna Spikevax Bivalent (BA.1) COVID-19 vaccine booster for 6 to 17 year olds [2023-02-17]
January 2023
- Health Canada is updating the COVID-19 clinical trial review time and is returning to the standard 30 day review [2023-01-27]
- Authorization of Moderna Spikevax COVID-19 vaccine booster dose for adolescents aged 12 to 17 years [2023-01-12]
December 2022
- Summary Basis of Decision (SBD) for COMIRNATY ORIGINAL/OMICRON BA.1 [2022-12-19]
- Summary Basis of Decision (SBD) for COMIRNATY ORIGINAL & OMICRON BA.4/BA.5 [2022-12-05]
- Updates to the Guidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19 [2022-12-16]
- Authorization of Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5 bivalent COVID-19 vaccine booster dose for children ages 5 to 11 years [2022-12-09]
- Authorization of Novavax Nuvaxovid COVID-19 vaccine for adolescent ages 12 to 17 years [2022-12-06]
November 2022
- Authorization of Novavax Nuvaxovid COVID-19 vaccine booster [2022-11-17]
- Authorization of Moderna Spikevax Original and Omicron BA.4/BA.5 bivalent COVID-19 vaccine booster [2022-11-03]
October 2022
- Authorization of Pfizer-BioNTech Comirnaty Original and Omicron BA.1 bivalent COVID-19 vaccine booster [2022-10-21]
- Evusheld COVID-19 expanded indication [2022-10-18]
- Actemra COVID-19 treatment authorization [2022-10-13]
- Authorization of Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5 bivalent COVID-19 vaccine booster [2022-10-07]
September 2022
- Authorization of Pfizer-BioNTech Comirnaty COVID-19 vaccine for children ages 6 months to 5 years [2022-09-09]
- Authorization of Moderna Spikevax Bivalent COVID-19 vaccine booster [2022-09-01]
August 2022
- Authorization of Pfizer-BioNTech Comirnaty COVID-19 vaccine first booster dose for children ages 5 to 11 years [2022-08-19]
- Janssen Jcovden (Johnson & Johnson) COVID-19 vaccine brand name authorization [2022-08-05]
July 2022
- Summary Basis of Decision (SBD) for EVUSHELD [2022-07-22]
- Authorization of Moderna Spikevax COVID-19 vaccine for children ages 6 months to 5 years [2022-07-14]
May 2022
- Summary Basis of Decision (SBD) for NUVAXOVID [2022-05-06]
- Summary Basis of Decision (SBD) for COVIFENZ [2022-05-04]
April 2022
- Remdesivir approved for treating COVID-19 in an outpatient setting [2022-04-22]
- Evusheld COVID-19 treatment [2022-04-14]
March 2022
- Summary Basis of Decision (SBD) for PAXLOVID [2022-03-21]
- Authorization of Moderna Spikevax COVID-19 vaccine for children ages 6-11 [2022-03-17]
- Notice: Clinical trials for medical devices and drugs relating to COVID-19 regulations [2022-03-02]
- Notice of updated guidance: Applications for COVID-19 drug clinical trials under the Regulations [2022-03-02]
- Notice: Period reduced for keeping clinical trial records for drugs and natural health products [2022-03-02]
February 2022
- Medicago Covifenz COVID-19 vaccine [2022-02-24]
- Novavax Nuvaxovid COVID-19 vaccine [2022-02-17]
January 2022
- Notice: Nirmatrelvir (COVID-19) added to Prescription Drug List (PDL) [2022-01-17]
- COVID-19: Nirmatrelvir and ritonavir (Paxlovid) treatment authorized for use in Canada [2022-01-17]
December 2021
- Access Consortium statement on COVID-19 medicines [2021-12-14]
November 2021
- What we heard report: Records retention consultations related to the clinical trials interim order transition regulations [2021-11-19]
- Authorization of Pfizer-BioNTech Comirnaty COVID-19 vaccine for children ages 5-11 [2021-11-19]
October 2021
September 2021
- Pfizer-BioNTech Comirnaty COVID-19 vaccine brand name authorization and transition into Food and Drug Regulations [2021-09-16]
- Moderna Spikevax COVID-19 vaccine brand name authorization and transition into Food and Drug Regulations [2021-09-16]
- AstraZeneca Vaxzevria COVID-19 vaccine brand name change through the Interim Order [2021-09-16]
- Access Consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines [2021-09-15]
- Summary Basis of Decision (SBD) for SOTROVIMAB [2021-09-10]
August 2021
July 2021
June 2021
May 2021
- Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19: Notice [2021-05-03]
- Applications for COVID-19 drug and medical device clinical trials under the interim order: Notice of updated guidance documents [2021-05-03]
April 2021
- COVID-19 clinical trials IO and clinical trials records retention: Consultation report [2021-04-16]
- Canada's approach to onsite inspections during COVID-19: Notice [2021-04-07]
March 2021
- Summary Basis of Decision (SBD) for JANSSEN COVID-19 VACCINE [2021-03-31]
- Updated requirements for COVID-19 drug authorizations: Notice [2021-03-31]
- What was heard: Consultation on interim order transition for tools to address drug and medical device shortages [2021-03-17]
- Summary Basis of Decision (SBD) for AstraZeneca COVID-19 Vaccine [2021-03-10]
- Janssen COVID-19 vaccine [2021-03-05]
- Access Consortium guidance on modifications to COVID-19 vaccines to address new variants of coronavirus [2021-03-04]
- Second Interim Order on Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 [2021-03-01]
February 2021
- AstraZeneca COVID-19 vaccine [2021-02-26]
January 2021
- Statement about confidence in COVID-19 vaccines for health care professionals [2021-01-20]
- Summary Basis of Decision (SBD) for Bamlanivimab for Injection [2021-01-08]
- Adverse Events Following Immunization Report [2020-01-08]
- Summary Basis of Decision (SBD) for the Moderna COVID-19 Vaccine [2021-01-06]
December 2020
- Moderna COVID-19 vaccine [2020-12-23]
- Bamlanivimab [2020-12-22]
- Ensuring predictability for COVID-19 clinical trials and proposal for clinical trials records retention: Notice to stakeholders [2020-12-10]
- Pfizer-BioNTech COVID-19 vaccine [2020-12-09]
- Vaccine development and approval in Canada (Infographic) [2020-12-08]
- COVID-19 mRNA vaccines [2020-12-08]
- Viral vector-based vaccines for COVID-19 [2020-12-08]
- Remdesivir (Veklury) [2020-12-08]
- Access Consortium statement on COVID-19 vaccines evidence [2020-12-03]
- Notice to stakeholders: Consultation on amending the Food and Drug Regulations to expedite access to COVID-19 drugs [2020-12-01]
- Consultation: Amending the Food and Drug Regulations to provide expedited access to COVID-19 drugs [2020-12-01]
November 2020
- Statement from Global Medicines Regulators on the Value of Regulatory Reliance [2020-11-27]
- Update on remdesivir: continued monitoring [2020-11-26]
- Ensuring predictability for interim orders relating to COVID-19: Notice to stakeholders [2020-11-23]
- Guidance for market authorization requirements for COVID-19 vaccines [2020-11-21]
- Regulatory Decision Summary for Bamlanivimab (COVID-19) [2020-11-20]
- Notice Prescription Drug List (PDL): Bamlanivimab (COVID-19) [2020-11-20]
October 2020
- Qualifying Notice for Veklury [2020-10-30]
- Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to COVID-19 [2020-10-19]
- Notice Interim order on preventing and alleviating drug shortages in relation to COVID-19 [2020-10-19]
- Health Canada's special access programs [2020-10-14]
- Notice to stakeholders: Final guidance document for industry and practitioners on the Special Access Program (SAP) for drugs [2020-10-14]
- Public release of clinical information for drugs and medical devices in COVID-19 interim orders applications: Guidance [2020-10-07]
September 2020
- Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 [2020-09-17]
- Interim order and guidance document to import, sell and advertise COVID-19 related drugs and vaccines: Notice [2020-09-17]
- Drug and vaccine authorizations for COVID-19 [2020-09-17]
August 2020
- Order to extend review period for clinical trial applications and amendments: Notice [2020-08-14]
- Good Manufacturing Practices and COVID-19 [2020-08-07]
- Drug establishment licences and COVID-19 [2020-08-07]
July 2020
- Notice: Prescription Drug List (PDL): Remdesivir (COVID-19) [2020-07-28]
- Regulatory Decision Summary for Veklury (remdesivir) [2020-07-28]
- Changes to notification requirements for biologic drugs: Notice to industry [2020-07-08]
- Health Canada's regulatory response to COVID-19: Access to health products [2020-07-03]
June 2020
May 2020
- Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19: Notice [2020-05-27]
- Applications for COVID-19 drug and medical device clinical trials under the Interim Order: Notice release of guidance documents [2020-05-27]
- Joint Statement on Clinical Trial Oversight in Canada [2020-05-27]
- Clinical trials and drug safety [2020-05-27]
- Australia, Canada, Singapore, Switzerland Consortium regulators pledge support to tackle COVID-19 [2020-05-05]
April 2020
- Engaging with international partners on COVID-19 [2020-04-30]
- International Coalition of Medicines Regulatory Authorities (ICMRA) statement on COVID-19 [2020-04-29]
- Management of clinical trials during the COVID-19 pandemic: Notice to clinical trial sponsors [2020-04-22]
- Health Product Advertising Incidents related to COVID-19 [2020-04-16]
- Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19 [2020-04-05]
- Exceptional importation and sale of drugs and biocides against COVID-19 [2020-04-05]
- Drugs and vaccines for COVID-19: Overview [2020-04-03]
- COVID-19 health product industry [2020-04-01]
2023
September
- Register of Innovative Drugs [2023-09-29]
- Notice of Compliance (NOC) Data Extracts [2023-09-29]
- Notice: Release of (Step 4) ICH M7(R2) Guideline, Addendum, Q&As - Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2023-09-29]
- Register of Innovative Drugs [2023-09-28]
- Register of Innovative Drugs [2023-09-22]
- Generic Submissions Under Review [2023-09-21]
- Submissions Under Review [2023-09-21]
- Updated Master file application form [2023-09-21]
- Product Monograph Brand Safety Updates – August 2023 [2023-09-20]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-09-19]
- Consultation on the changes to the 2020 product monograph guidance and master template [2023-09-15]
- Notice of Compliance (NOC) Data Extracts [2023-09-15]
- Register of Innovative Drugs [2023-09-15]
- Summary Basis of Decision for Imcivree [2023-09-12]
- Summary Basis of Decision for Onakta [2023-09-12]
- Summary Basis of Decision for Quviviq [2023-09-12]
- Summary Basis of Decision for Winlevi [2023-09-12]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-09-06]
- DPD Extracts [2023-09-01]
- Notice of Compliance (NOC) Data Extracts [2023-09-01]
August
- Notice: Multiple additions to the Prescription Drug List (PDL) [2023-08-30]
- Updated List of Drugs for an Urgent Public Health Need [2023-08-24]
- Register of Innovative Drugs [2023-08-22]
- Notice of Compliance (NOC) Data Extracts [2023-08-18]
- Product Monograph Brand Safety Updates – July 2023 [2023-08-18]
- Generic Submissions Under Review [2023-08-17]
- Submissions Under Review [2023-08-17]
- Consultation: Draft guidance on the preparation of the product monograph in XML format [2023-08-15]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-08-15]
- Register of Innovative Drugs [2023-08-11]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-08-09]
- Notice of Compliance (NOC) Data Extracts [2023-08-04]
- Qualifying notice for Tecvayli [2023-08-03]
- Register of Innovative Drugs [2023-08-03]
- Qualifying notice for Lynparza [2023-08-02]
- DPD Extracts [2023-08-01]
July
- Register of Innovative Drugs [2023-07-28]
- Updated: Guidance on nitrosamine impurities in medications [2023-07-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-07-28]
- Generic Submissions Under Review [2023-07-26]
- Submissions Under Review [2023-07-26]
- Notice: Release of (Step 4) ICH S12 Guideline - Nonclinical Biodistribution Considerations for Gene Therapy Products [2023-07-21]
- Notice of Compliance (NOC) Data Extracts [2023-07-21]
- Updated Master file application form [2023-07-19]
- Product Monograph Brand Safety Updates – June 2023 [2023-07-17]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-07-17]
- Notice of Compliance (NOC) Data Extracts [2023-07-07]
- Qualifying notice for Ondexxya [2023-07-05]
- DPD Extracts [2023-07-04]
June
- Register of Innovative Drugs [2023-06-30]
- Updated: Regulatory enrolment process [2023-06-27]
- Summary Basis of Decision for Beyfortus [2023-06-27]
- Summary Basis of Decision for Locametz [2023-06-27]
- Summary Basis of Decision for Spevigo [2023-06-27]
- Summary Basis of Decision for Qulipta [2023-06-27]
- Updated: Guidance on procedures and administrative requirements for master files [2023-06-26]
- Qualifying notice for Akeega [2023-06-23]
- Generic Submissions Under Review [2023-06-23]
- Notice of Compliance (NOC) Data Extracts [2023-06-23]
- Submissions Under Review [2023-06-23]
- Notice: Multiple additions to the Prescription Drug List (PDL) [2023-06-23]
- Statistical Report 2022/2023 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection and Certificates of Supplementary Protection [2023-06-23]
- Register of Innovative Drugs [2023-06-22]
- Consultation: Release of Draft (Step 2) ICH guideline, ICH E6(R3) [2023-06-21]
- Product Monograph Brand Safety Updates – May 2023 [2023-06-20]
- S1B(R1): Health Canada Notice [2023-06-20]
- S1B(R1): Guideline - Testing for Carcinogenicity of Pharmaceuticals [2023-06-20]
- Update: Guidance document: preparation of regulatory activities in non-eCTD format [2023-06-16]
- Implementing the regulatory enrolment process (REP) for medical devices regulatory activities: Notice [2023-06-15]
- Submissions Under Review [2023-06-14]
- Generic Submissions Under Review [2023-06-14]
- Notice of Compliance (NOC) Data Extracts [2023-06-09]
- Register of Innovative Drugs [2023-06-09]
- Summary Basis of Decision (SBD) for Alhemo [2023-06-06]
- Summary Basis of Decision (SBD) for Carvykti [2023-06-06]
- Summary Basis of Decision (SBD) for Columvi [2023-06-06]
- Summary Basis of Decision (SBD) for Vegzelma [2023-06-06]
- Consultation on improving access to drugs and other health products in Canada [2023-06-05]
- Updated: Organisation and Document Placement for Canadian Module 1 [2023-06-05]
- Veterinary drugs master file updates and fees consultation: Notice [2023-06-02]
- DPD Extracts [2023-06-01]
May
- Notice of Amendment: Correction to the Moxidectin Veterinary Listing on the Prescription Drug List (PDL) [2023-05-31]
- Summary Basis of Decision (SBD) for Empaveli [2023-05-30]
- Summary Basis of Decision for Camzyos [2023-05-30]
- Summary Basis of Decision for Kengrexal [2023-05-30]
- Summary Basis of Decision for Mounjaro [2023-05-30]
- Summary Basis of Decision for Sunlenca [2023-05-30]
- Notice of Compliance (NOC) Data Extracts [2023-05-26]
- Register of Innovative Drugs [2023-05-25]
- Qualifying notice for Thiotepa For Injection, BP (256254) [2023-05-23]
- Register of Innovative Drugs [2023-05-19]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-05-18]
- Product Monograph Brand Safety Updates – April 2023 [2023-05-15]
- Notice of Compliance (NOC) Data Extracts [2023-05-12]
- Register of Innovative Drugs [2023-05-12]
- Notice: Publication of the Guidance Document: Certificates of Supplementary Protection [2023-05-12]
- Updated Submissions Under Review [2023-05-08]
- Generic Submissions Under Review [2023-05-08]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-05-05]
- Register of Innovative Drugs [2023-05-05]
- Summary Basis of Decision (SBD) for UBRELVY [2023-05-05]
- Summary Basis of Decision (SBD) for ELONOX/ELONOX HP [2023-05-05]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-05-03]
- DPD Extracts [2023-01-05]
- New Master File Application Form: Notice [2023-05-01]
April
- Updated Register of Certificates of Supplementary Protection and Applications [2023-05-23]
- Notice of Compliance (NOC) Data Extracts [2023-05-02]
- Register of Innovative Drugs [2023-05-02]
- Product Monograph Brand Safety Updates – March 2023 [2023-05-02]
- Qualifying notice for Columvi [2023-04-17]
- Nitrosamine impurities in medications: Guidance [2023-04-17]
- Notice of Compliance (NOC) Data Extracts [2023-04-14]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-04-12]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-04-04]
- DPD Extracts [2023-04-03]
- Updated List of Drugs for an Urgent Public Health Need [2023-04-03]
March
- Summary Basis of Decision (SBD) for ERVEBO [2023-03-31]
- Summary Basis of Decision (SBD) for MOUNJARO [2023-03-31]
- Summary Basis of Decision (SBD) for SOTYKTU [2023-03-31]
- Summary Basis of Decision (SBD) for SUNLENCA [2023-03-31]
- Notice of Compliance (NOC) Data Extracts [2023-03-31]
- Register of Innovative Drugs [2023-03-31]
- Canada's approach to drugs for children and youth [2023-03-27]
- Consultation: Proposed application of the definition of Canadian Reference Product (CRP) [2023-03-27]
- Dear Health Care Professional Letter : Istodax [2023-03-24]
- Generic Submissions Under Review [2022-03-24]
- Submissions Under Review [2022-03-24]
- Serious adverse drug reactions and medical device incidents reported by Canadian hospitals [2023-03-23]
- Register of Innovative Drugs [2023-03-23]
- Product Monograph Brand Safety Updates - February 2023 [2023-03-23]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-03-20]
- Register of Innovative Drugs [2023-03-17]
- Notice of Compliance (NOC) Data Extracts [2023-03-17]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-03-15]
- Health Canada changes filing requirements for product monographs: Notice [2023-03-10]
- Summary Basis of Decision (SBD) for ILLUCCIX [2023-03-10]
- Summary Basis of Decision (SBD) for KERENDIA [2023-03-10]
- Summary Basis of Decision (SBD) for LIVTENCITY [2023-03-10]
- Summary Basis of Decision (SBD) for RYMTI [2023-03-10]
- Register of Innovative Drugs [2023-03-09]
- Notice to stakeholders - Clarification of requirements under the Food and Drug Regulations when conducting clinical trials with cannabis [2023-03-09]
- Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08]
- Qualifying notice for Carvykti [2023-03-07]
- Consultation period extended until April 26, 2023 for proposed agile regulations and guidance for licensing drugs and medical devices [2023-03-06]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-03-06]
- Notice of Compliance (NOC) Data Extracts [2023-03-03]
- DPD Extracts [2023-03-01]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-03-01]
February
- Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy [2023-02-27]
- Qualifying notice for Lucentis [2023-02-24]
- Consultation: Release of Draft (Step 2) ICH guideline, ICH M13 [2023-02-24]
- Submissions Under Review [2023-02-24]
- Generic Submissions Under Review [2023-02-24]
- Consultation: Registration of Clinical Trials and Public Disclosure of Results: Draft Guidance and Public Search Portal [2023-02-23]
- Notice of Compliance (NOC) Data Extracts [2023-02-17]
- Register of Innovative Drugs [2023-02-17]
- New products for serious adverse drug reaction hospital reporting: Notice [2023-02-15]
- Summary Basis of Decision (SBD) for CIBINQO [2023-02-14]
- Summary Basis of Decision (SBD) for MYXREDLIN [2023-02-14]
- Summary Basis of Decision (SBD) for PLUVICTO [2023-02-14]
- Summary Basis of Decision (SBD) for WELIREG [2023-02-14]
- Product Monograph Brand Safety Updates - January 2023 [2023-02-14]
- Register of Innovative Drugs [2023-02-10]
- Qualifying notice for Ocaliva [2022-02-07]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-02-07]
- Notice of Compliance (NOC) Data Extracts [2023-02-03]
- Register of Innovative Drugs [2023-02-03]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-02-01]
- DPD Extracts [2023-02-01]
January
- Qualifying notice for Opdivo [2023-01-30]
- Updated: Guidance Document Conduct and Analysis of Comparative Bioavailability Studies [2023-01-30]
- Qualifying notice amendment for Opdivo [2023-01-25]
- Generic Submissions Under Review [2023-01-24]
- Submissions Under Review [2023-01-24]
- Drug shortages in Canada: Information for consumers [2023-01-20]
- Notice of Compliance (NOC) Data Extracts [2023-01-20]
- Summary Basis of Decision (SBD) for ALBRIOZA [2023-01-20]
- Summary Basis of Decision (SBD) for KORSUVA [2023-01-20]
- Summary Basis of Decision (SBD) for KOSELUGO [2023-01-20]
- Summary Basis of Decision (SBD) for TEZSPIRE [2023-01-20]
- Notice: Release of (Step 4) ICH M10 Guideline and Q&A Document - Bioanalytical Method Validation and Study Sample Analysis [2023-01-20]
- Notice: Joint Health Canada, Canada and FDA, United States Public Consultation on ICH [2023-01-17]
- Updated Register of Certificates of Supplementary Protection and Applications [2023-01-16]
- Product Monograph Brand Safety Updates - December 2022 [2023-01-12]
- Register of Innovative Drugs [2023-01-06]
- Notice of Compliance (NOC) Data Extracts [2023-01-06]
- Notice of Amendment: Betaine removed from the Prescription Drug List (PDL) [2023-01-06]
- DPD Extracts [2023-01-03]
2022
December
- Summary Basis of Decision (SBD) for COMIRNATY ORIGINAL/OMICRON BA.1 [2022-12-19]
- Summary Basis of Decision (SBD) for COMIRNATY ORIGINAL & OMICRON BA.4/BA.5 [2022-12-05]
- Qualifying notice for Kymriah [2022-12-30]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-12-29]
- Notice of Compliance (NOC) Data Extracts [2022-12-22]
- Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-12-22]
- Product Monograph Brand Safety Updates - November 2022 [2022-12-19]
- Consultation on proposed agile regulations and guidance for licensing drugs and medical devices [2022-12-16]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-12-16]
- Register of Innovative Drugs [2022-12-16]
- Submissions Under Review [2022-12-13]
- Generic Submissions Under Review [2022-12-13]
- Non-prescription Drug Action Plan [2022-12-08]
- Notice of Compliance (NOC) Data Extracts [2022-12-08]
- Notice to stakeholders: Health Canada's expectations regarding risk-management measures for clinical trials involving psychedelic-assisted psychotherapy [2022-12-05]
- Register of Innovative Drugs [2022-12-02]
- DPD Extracts [2022-12-01]
November
- Updated Register of Certificates of Supplementary Protection and Applications [2022-11-28]
- Register of Innovative Drugs [2022-11-25]
- Notice of Compliance (NOC) Data Extracts [2022-11-25]
- Summary Basis of Decision (SBD) for ORLADEYO [2022-11-24]
- Summary Basis of Decision (SBD) for POTELIGEO [2022-11-24]
- Summary Basis of Decision (SBD) for XPOVIO [2022-11-24]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-11-18]
- Consultation: Release of Draft (Step 2) ICH M11 guideline, technical specification and template [2022-11-18]
- Register of Innovative Drugs [2022-11-17]
- Qualifying notice for HepaGam B [2022-11-17]
- Updated List of Drugs for an Urgent Public Health Need [2022-11-17]
- Register of Innovative Drugs [2022-11-10]
- Notice of Compliance (NOC) Data Extracts [2022-11-10]
- Submissions Under Review [2022-11-10]
- Generic Submissions Under Review [2022-11-10]
- Product Monograph Brand Safety Updates - October 2022 [2022-11-10]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-11-09]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-11-07]
- Updated: REP guidance document for Human Drugs, Veterinary Drugs and Disinfectants [2022-11-04]
- Register of Innovative Drugs [2022-11-04]
- Consultation: Release of Draft (Step 2) ICH guideline, ICH Q5A(R2) [2022-11-02]
- DPD Extracts [2022-11-01]
October
- Register of Innovative Drugs [2022-10-28]
- Notice of Compliance (NOC) Data Extracts [2022-10-28]
- Infant and children's acetaminophen and ibuprofen shortage [2022-10-26]
- Register of Innovative Drugs [2022-10-21]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-10-20]
- Submissions Under Review [2022-10-20]
- Generic Submissions Under Review [2022-10-20]
- Summary Basis of Decision (SBD) for BIMZELX [2022-10-18]
- Summary Basis of Decision (SBD) for KIMMTRAK [2022-10-18]
- Summary Basis of Decision (SBD) for SCEMBLIX [2022-10-18]
- Notice of Compliance (NOC) Data Extracts [2022-10-14]
- Notice: Multiple additions to the Prescription Drug List (PDL) [2022-10-14]
- Product Monograph Brand Safety Updates - September 2022 [2022-10-13]
- Qualifying notice for Yescarta [2022-10-07]
- DPD Extracts [2022-10-03]
- Health Canada to monitor the inclusion of disaggregated data in clinical evidence: Notice to stakeholders [2022-10-03]
- Notice of Compliance (NOC) Data Extracts [2022-10-03]
September
- Consultation Extension: Draft (Step 2) ICH Guideline E11A [2022-09-29]
- Updated: Regulatory enrolment process [2022-09-29]
- Updated List of Drugs for an Urgent Public Health Need [2022-09-27]
- Summary Basis of Decision (SBD) for BREYANZI [2022-09-27]
- Summary Basis of Decision (SBD) for BYOOVIZ [2022-09-27]
- Summary Basis of Decision (SBD) for PREVNAR 20 [2022-09-27]
- Summary Basis of Decision (SBD) for SEMGLEE [2022-09-27]
- Summary Basis of Decision (SBD) for VABYSMO [2022-09-27]
- Summary Basis of Decision (SBD) for TABRECTA [2022-09-27]
- Summary Basis of Decision (SBD) for TAVNEOS [2022-09-27]
- Summary Basis of Decision (SBD) for VRAYLAR [2022-09-27]
- Register of Innovative Drugs [2022-09-23]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-09-21]
- Notice of Compliance (NOC) Data Extracts [2022-09-20]
- Generic Submissions Under Review [2022-09-16]
- Submissions Under Review [2022-09-16]
- Updated: Guidance document preparation of regulatory activities in non-eCTD format [2022-09-15]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-09-14]
- Product Monograph Brand Safety Updates - August 2022 [2022-09-14]
- Guidance on veterinary drug labelling [2022-09-13]
- Register of Innovative Drugs [2022-09-09]
- Notice of Compliance (NOC) Data Extracts [2022-09-02]
- Register of Innovative Drugs [2022-09-02]
- Updated: REP guidance document for human drugs, veterinary drugs and disinfectants [2022-09-02]
- Updated: Guidance on nitrosamine impurities in medications [2022-09-01]
- DPD Extracts [2022-09-01]
August
- Notice: Implementation of (Step 4) ICH Q3D(R2) Guideline - Revision of Q3D(R1) for cutaneous and transdermal products [2022-08-29]
- Recommandations de Santé Canada sur la mise en œuvre de la directive harmonisée révisée Q3D (R2) de l'ICH concernant les impuretés élémentaires pour les produits cutanés et transdermiques [2022-08-29]
- Register of Innovative Drugs [2022-08-26]
- Updated: Clinical Trial Applications in eCTD format [2022-08-26]
- Notice of Compliance (NOC) Data Extracts [2022-08-19]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-08-19]
- Summary Basis of Decision (SBD) for PALYNZIQ [2022-08-17]
- Summary Basis of Decision (SBD) for RHOLISTIQ [2022-08-17]
- Summary Basis of Decision (SBD) for RYBREVANT [2022-08-17]
- Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-08-17]
- Product Monograph Brand Safety Updates - July 2022 [2022-08-12]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-08-11]
- Generic Submissions Under Review [2022-08-11]
- Submissions Under Review [2022-08-11]
- Notice of Compliance (NOC) Data Extracts [2022-08-05]
- Register of Innovative Drugs [2022-08-05]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-08-04]
- Health product highlights 2021: Helping you maintain and improve your health [2022-08-03]
- DPD Extracts [2022-08-02]
- Qualifying notice for Lynparza [2022-08-02]
- Notice: Revision to the Guidance Document Management of Drug Submissions and Applications (August 2022) [2022-08-02]
- Notice: Revisions to the performance standards for Post-authorization Division 1 Changes [2022-08-02]
- Updated: Guidance Document Post-Drug Identification Number (DIN) Changes [2022-08-02]
July
- Consultation: Release of Draft (Step 2) ICH guideline, ICH M12 [2022-07-29]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-07-28]
- Consultation: Exceptions to the Prescription Drug List [2022-07-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-07-26]
- PDD/BRDD/NNHPD Drug Submission Performance Annual Report - Fiscal Year 2021-2022 [2022-07-25]
- Register of Innovative Drugs [2022-07-25]
- Summary Basis of Decision (SBD) for EVUSHELD [2022-07-22]
- Summary Basis of Decision (SBD) for HYQVIA [2022-07-22]
- Summary Basis of Decision (SBD) for ONTRUZANT [2022-07-22]
- Summary Basis of Decision (SBD) for OXLUMO [2022-07-22]
- Summary Basis of Decision (SBD) for RHOLISTIQ [2022-07-22]
- Summary Basis of Decision (SBD) for RYBREVANT [2022-07-22]
- Summary Basis of Decision (SBD) for SOHONOS [2022-07-22]
- Generic Submissions Under Review [2022-07-22]
- Notice of Compliance (NOC) Data Extracts [2022-07-22]
- Submissions Under Review [2022-07-21]
- Fees for Master Files for Human Drugs [2022-07-20]
- Notice of Amendment: Addition of Metamizole (Dipyrone) to the Prescription Drug List (PDL) [2022-07-18]
- Product Monograph Brand Safety Updates [2022-07-12]
- Register of Innovative Drugs [2022-07-11]
- Notice of Compliance (NOC) Data Extracts [2022-07-08]
- Notice of Intent to Amend the Prescription Drug List (PDL): Betaine [2022-07-06]
- DPD Extracts [2022-07-04]
- Summary Basis of Decision (SBD) for NETVISION [2022-07-04]
June
- PDD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q4-2021-2022 [2022-06-30]
- Register of Innovative Drugs [2022-06-30]
- Notice of change to the DPD Extracts effective July 1, 2022 [2022-06-30]
- Qualifying notice for Thiotepa for Injection USP [2022-06-28]
- Updated: Organisation and Document Placement for Canadian Module 1 [2022-06-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-06-28]
- Notice of Compliance (NOC) Data Extracts [2022-06-24]
- Generic Submissions Under Review [2022-06-22]
- Qualifying notice for Tabrecta [2022-06-24]
- Submissions Under Review [2022-06-22]
- Product Monograph Brand Safety Updates - May 2022 [2022-06-20]
- Notice: Multiple additions to the Prescription Drug List (PDL) [2022-06-17]
- Register of Innovative Drugs [2022-06-16]
- Draft ICH guideline Q2(R2): Revision to Analytical Validation [2022-06-13]
- Draft ICH guideline Q14: Analytical Procedure Development [2022-06-13]
- Draft ICH guideline E11A: Paediatric Extrapolation [2022-06-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-06-13]
- Qualifying notice for Albrioza [2022-06-13]
- Notice: Release of Final (Step 4) ICH Q&A Document, ICH E14/S7B: Questions & Answers - Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential [2022-06-10]
- Register of Innovative Drugs [2022-06-10]
- Notice of Compliance (NOC) Data Extracts [2022-06-10]
- Register of Innovative Drugs [2022-06-03]
- Notice: New products for serious adverse drug reaction hospital reporting [2022-06-01]
- DPD Extracts [2022-06-01]
May
- Notice of Compliance (NOC) Data Extracts [2022-05-27]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-05-24]
- Submissions Under Review [2022-05-19]
- Generic Submissions Under Review [2022-05-19]
- Updated: Validation rules for regulatory transactions provided to Health Canada in the non-eCTD format [2022-05-13]
- Updated: Validation rules for regulatory transactions provided to Health Canada in the electronic Common Technical Document (eCTD) format [2022-05-13]
- Notice of Amendment: Revision of Brimonidine on the Prescription Drug List (PDL) [2022-05-16]
- Notice of Compliance (NOC) Data Extracts [2022-05-13]
- Product Monograph Brand Safety Updates - April 2022 [2022-05-12]
- Register of Innovative Drugs [2022-05-13]
- Summary Basis of Decision (SBD) for NUVAXOVID [2022-05-06]
- Summary Basis of Decision (SBD) for SIMLANDI [2022-05-06]
- Summary Basis of Decision (SBD) for YUFLYMA [2022-05-06]
- Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) [2022-05-06]
- Summary Basis of Decision (SBD) for ABEVMY [2022-05-04]
- Summary Basis of Decision (SBD) for ADTRALZA [2022-05-04]
- Summary Basis of Decision (SBD) for COVIFENZ [2022-05-04]
- Summary Basis of Decision (SBD) for IXIFI [2022-05-04]
- Summary Basis of Decision (SBD) for JEMPERLI [2022-05-04]
- DPD Extracts [2022-05-02 ]
April
- Qualifying notice for Rybrevant [2022-04-28]
- Qualifying notice for Gardasil 9 [2022-04-26]
- Notice of Compliance (NOC) Data Extracts [2022-04-29]
- Register of Innovative Drugs [2022-04-29]
- Blood safety in Canada: Restriction lifted for men who have sex with men [2022-04-28]
- Notice: Interim implementation of electronic labelling for human prescription drugs [2022-04-22]
- Register of Innovative Drugs [2022-04-22]
- Comment on the draft revised Guidance document: Switching a medicinal ingredient from prescription to non-prescription status [2022-04-21]
- Submissions Under Review [2022-04-14]
- Notice of Compliance (NOC) Data Extracts [2022-04-14]
- Generic Submissions Under Review [2022-04-14]
- Register of Innovative Drugs [2022-04-14]
- Product Monograph Brand Safety Updates - March 2022 [2022-04-14]
- Updated List of Drugs for an Urgent Public Health Need [2022-04-12]
- Updated: Special Access Program for drugs: Guidance document for industry and practitioners [2022-04-11]
- Keeping Health Products In Canada Safe [2022-04-05]
- Register of Innovative Drugs [2022-04-07]
- Updated List of Drugs for an Urgent Public Health Need [2022-04-07]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-04-04]
- Updated: Health Canada 3011: Drug Submission Application Form for Human, Veterinary or Disinfectant Drugs and Clinical Trial Application/Attestation[2022-04-04]
- Notice for the updated 2022 fees for the Master File Application Fee form [2022-04-04]
- Qualifying notice for Bavencio [2022-04-04]
- DPD Extracts [2022-04-01]
- Notice of Compliance (NOC) Data Extracts [2022-04-01]
- Updated: Regulatory enrolment process [2022-04-01]
March
- Register of Innovative Drugs [2022-03-31]
- Notice of Amendment: Tramadol removed from the Prescription Drug List (PDL) [2022-03-31]
- Notice of change to the DPD Extracts effective April 1, 2022 [2022-03-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-03-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-03-23]
- Updated: Qualified investigator undertaking [2022-03-23]
- Summary Basis of Decision (SBD) for NEXVIAZYME [2022-03-21]
- Summary Basis of Decision (SBD) for PEMAZYRE [2022-03-21]
- Summary Basis of Decision (SBD) for TPOXX [2022-03-21]
- Summary Basis of Decision (SBD) for VAXNEUVANCE [2022-03-21]
- Updated: Research Ethics Board attestation [2022-03-18]
- Register of Innovative Drugs [2022-03-18]
- Notice of Compliance (NOC) Data Extracts [2022-03-18]
- Submissions Under Review [2022-03-15]
- Generic Submissions Under Review [2022-03-15]
- TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q3-2021-2022 [2022-03-11]
- Register of Innovative Drugs [2022-03-11]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-03-10]
- Product Monograph Brand Safety Updates - February 2022 [2022-03-09]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-03-04]
- Notice of change to the DPD Extracts effective March 1, 2022 [2022-03-04]
- Notice of Compliance (NOC) Data Extracts [2022-03-04]
- Health Canada 3011: Drug Submission Application Form for Human, Veterinary or Disinfectant Drugs and Clinical Trial Application/Attestation [2022-03-03 ]
- Updated: Filing submissions electronically [2022-03-04]
- Notice: Regulations amending certain regulations concerning drugs and medical devices (shortages) [2022-03-02]
- Drug shortages in Canada: Regulations and guidance [2022-03-02]
- DPD Extracts [2022-03-01]
February
- Updated: Guidance Document - Preparation of Regulatory Activities in Non-eCTD format and Filing Submission Electronically webpage [2022-02-28]
- Submissions Under Review [2022-02-25]
- Register of Innovative Drugs [2022-02-25]
- What we heard report on the clinical trials regulatory modernization initiative [2022-02-23]
- Summary Basis of Decision (SBD) for AYBINTIO [2022-02-22]
- Summary Basis of Decision (SBD) for NYPOZI [2022-02-22]
- Summary Basis of Decision (SBD) for PADCEV [2022-02-22]
- Summary Basis of Decision (SBD) for SAPHNELO [2022-02-22]
- Register of Innovative Drugs [2022-02-18]
- Notice of Compliance (NOC) Data Extracts [2022-02-18]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-02-17]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Summary of findings and advice, October 27th, 2021 virtual meeting [2022-02-16]
- Submissions Under Review [2022-02-16]
- Generic Submissions Under Review [2022-02-15]
- Product Monograph Brand Safety Updates - January 2022 [2022-02-14]
- Summary Basis of Decision (SBD) for BAMBEVI [2022-02-11]
- Summary Basis of Decision (SBD) for KIRSTY [2022-02-11]
- Summary Basis of Decision (SBD) for NGENLA [2022-02-11]
- Summary Basis of Decision (SBD) for RUKOBIA [2022-02-11]
- Summary Basis of Decision (SBD) for ZEPZELCA [2022-02-11]
- Updated: Guidance Document: Regulatory requirements for Drug Identification Numbers (DINs) [2022-02-10]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-02-10]
- Notice of Compliance (NOC) Data Extracts [2022-02-04]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-02-04]
- DPD Extracts [2022-02-01]
January
- Updated Register of Certificates of Supplementary Protection and Applications [2022-01-28]
- Register of Innovative Drugs [2022-01-28]
- Updated: Clinical Trial Site Information Form [2022-01-20]
- Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]
- Notice of Compliance (NOC) Data Extracts [2022-01-21]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-01-21]
- Updated List of Drugs for an Urgent Public Health Need [2022-01-21]
- Generic Submissions Under Review [2022-01-19]
- Submissions Under Review [2022-01-19]
- Product Monograph Brand Safety Updates - December 2021 [2022-01-19]
- Notice: Prescription Drug List (PDL): Metamizole (dipyrone) [2022-01-18]
- Notice: Update to the Guidance Document: Master Files (MFs) - Procedures and Administrative Requirements Effective January 1, 2022 [2022-01-14]
- Consultation: Release of Draft ICH : Q9(R1): Quality Risk Management [2022-01-14]
- ICH E8(R1): General Considerations for Clinical Studies [2022-01-14]
- Summary Basis of Decision (SBD) for LUMAKRAS [2022-01-11]
- Summary Basis of Decision (SBD) for OSPHENA [2022-01-11]
- Summary Basis of Decision (SBD) for TECARTUS [2022-01-11]
- Summary Basis of Decision (SBD) for TRODELVY [2022-01-11]
- Summary Basis of Decision (SBD) for TRUSELTIQ [2022-01-11]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-01-11]
- Notice to Stakeholders - Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin [2022-01-11]
- Joint Notice on Collaboration between the Competition Bureau and Health Products and Food Branch of Health Canada [2022-01-10]
- Register of Innovative Drugs [2022-01-07]
- Notice of Compliance (NOC) Data Extracts [2022-01-07]
- Updated Register of Certificates of Supplementary Protection and Applications [2022-01-06]
- Guidance Document: Special Access Program for Drugs: Guidance Document for Industry and Practitioners [2022-01-05]
- DPD Extracts [2022-01-04 ]
2021
December
- Notice of Compliance (NOC) Data Extracts [2021-12-30]
- TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q2-2021-2022 [2021-12-23]
- Generic Submissions Under Review [2021-12-22]
- Submissions Under Review [2021-12-22]
- Notice of Consultation on the Prescription Drug List (PDL): Betaine [2021-12-22]
- Operational procedures for New Active Substances Work-Sharing Initiative (NASWSI) [2021-12-17]
- Register of Innovative Drugs [2021-12-17]
- Notice of Compliance (NOC) Data Extracts [2021-12-16]
- Product Monograph Brand Safety Updates - November 2021 [2021-12-16]
- Submissions Under Review [2021-12-14]
- Generic Submissions Under Review [2021-12-14]
- Qualifying Notice for Keytruda [2021-12-10]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Summary of findings and advice, June 23rd, 2021 virtual meeting [2021-12-10]
- Register of Innovative Drugs [2021-12-09]
- Summary Basis of Decision (SBD) for ABECMA [2021-12-08]
- Summary Basis of Decision (SBD) for GAVRETO [2021-12-08]
- Summary Basis of Decision (SBD) for LEQVIO [2021-12-08]
- Summary Basis of Decision (SBD) for MINJUVI [2021-12-08]
- Summary Basis of Decision (SBD) for RIABNI [2021-12-08]
- Notice: Prescription Drug List (PDL): Epinephrine (Topical Solution) [2021-12-06]
- Register of Innovative Drugs [2021-12-03]
- DPD Extracts [2021-12-01]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-12-01]
November
- Summary Basis of Decision (SBD) for RETEVMO [2021-11-29]
- Summary Basis of Decision (SBD) for TEPMETKO [2021-11-29]
- Summary Basis of Decision (SBD) for TRIKAFTA [2021-11-29]
- Notice - Interim Implementation of International Council for Harmonisation (ICH) Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management [2021-11-29]
- Notice of Compliance (NOC) Data Extracts [2021-11-26]
- Extension: Release of draft revised guidance documents on Post-Notice of Compliance (NOC) Changes - Quality, for stakeholder consultation [2021-11-26]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-11-25]
- Updated: Regulatory enrolment process [2021-11-23]
- Register of Innovative Drugs [2021-11-18]
- Product Monograph Brand Safety Updates - October 2021 [2021-11-15]
- Notice: Prescription Drug List (PDL): Brimonidine [2021-11-15]
- Notice: Prescription Drug List (PDL): Multiple Additions [2021-11-15]
- Notice of Compliance (NOC) Data Extracts [2021-11-12]
- Updated List of Drugs for an Urgent Public Health Need [2021-11-12]
- Consultation: Release of Draft (Step 2) ICH Guideline: M7(R2): Addendum to the Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2021-11-12]
- Guide to distributing drugs intended for the Canadian market for consumption or use outside Canada (GUI-0145) [2021-11-10]
- Guide on the requirements for providing information related to drug shortages (GUI-0146) [2021-11-10]
- Statistical Report 2020/2021 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection and Certificates of Supplementary Protection [2021-11-10]
- Updated List of Drugs for an Urgent Public Health Need [2021-11-09]
- Notice: Update on Health Canada's implementation of ICH's Q12 guideline and pilot programs [2021-11-05]
- Register of Innovative Drugs [2021-11-05]
- Updated: Filing submissions electronically [2021-11-05]
- Submissions Under Review [2021-11-03]
- DPD Extracts [2021-11-01]
October
- Register of Innovative Drugs [2021-10-29]
- Notice of Compliance (NOC) Data Extracts [2021-10-29]
- Consultation: Release of Draft (Step 2) ICH Guidance: Q13: Continuous Manufacturing of Drug Substances and Drug Products [2021-10-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-10-27]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Agenda [2021-10-26]
- Submissions Under Review [2021-10-25]
- Generic Submissions Under Review [2021-10-25]
- Register of Innovative Drugs [2021-10-22]
- Notice: Prescription Drug List (PDL): Multiple Additions [2021-10-21]
- Qualifying Notice for Zepzelca [2021-10-19]
- Extension: Release of draft revised guidance documents on Post-Notice of Compliance (NOC) Changes - Quality, for stakeholder consultation [2021-10-15]
- Notice of Compliance (NOC) Data Extracts [2021-10-15]
- Register of Innovative Drugs [2021-10-15]
- Product Monograph Brand Safety Updates - September 2021 [2021-10-14]
- DPD Extracts [2021-10-05]
- Summary Basis of Decision (SBD) for ABRILADA (FORMERLY ADALIMUMAB INJECTION) [2021-10-12]
- Summary Basis of Decision (SBD) for ILUMYA [2021-10-12]
- Summary Basis of Decision (SBD) for SUNOSI [2021-10-12]
- Summary Basis of Decision (SBD) for WAKIX [2021-10-12]
- Register of Innovative Drugs [2021-10-07]
- Qualifying Notice for Truseltiq [2021-10-07]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-10-07]
- Mid-year update: Health products approved in 2021
- Updated List of Drugs for an Urgent Public Health Need [2021-10-06]
- Qualifying Notice for Pemazyre [2021-10-04]
- DPD Extracts [2021-10-01]
- Notice of Compliance (NOC) Data Extracts [2021-10-01]
September
- TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q1-2021-2022 [2021-09-29]
- Prescription status of edaravone and personal importation: Notice of update [2021-09-29]
- Register of Innovative Drugs [2021-09-24]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-09-24]
- Qualifying Notice for Lumakras [2021-09-23]
- Qualifying Notice for Minjuvi [2021-09-20]
- Register of Innovative Drugs [2021-09-17]
- Generic Submissions Under Review [2021-09-17]
- Notice of Compliance (NOC) Data Extracts [2021-09-17]
- Submissions Under Review [2021-09-17]
- Product Monograph Brand Safety Updates - August 2021 [2021-09-10]
- Notice: Prescription Drug List (PDL): Multiple Additions [2021-09-10]
- Summary Basis of Decision (SBD) for EVRYSDI [2021-09-10]
- Summary Basis of Decision (SBD) for HULIO [2021-09-10]
- Summary Basis of Decision (SBD) for PONVORY [2021-09-10]
- Summary Basis of Decision (SBD) for TRIFERIC AVNU [2021-09-10]
- Notice of Compliance (NOC) Data Extracts [2021-09-03]
- Register of Innovative Drugs [2021-09-03]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-09-02]
- Regulations amending certain regulations concerning drugs and medical devices (shortages): Notice [2021-09-01]
- DPD Extracts [2021-09-01]
- Notice of Consultation on the Prescription Drug List (PDL): Brimonidine [2021-09-01]
August
- Notice of Compliance (NOC) Data Extracts [2021-08-31]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-08-31]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2021-08-26]
- Updated: Qualified investigator undertaking [2021-08-17]
- Updated: Research Ethics Board attestation [2021-08-17]
- Submissions Under Review [2021-08-17]
- Generic Submissions Under Review [2021-08-17]
- Register of Innovative Drugs [2021-08-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-08-11]
- Product Monograph Brand Safety Updates - July 2021 [2021-08-11]
- The Drug Establishment Licensing Bulletin [2021-08-10]
- Notice of Compliance (NOC) Data Extracts [2021-08-06]
- Notice: Release of draft revised guidance documents on Post-Notice of Compliance (NOC) Changes - Quality, for stakeholder consultation [2021-08-06]
- Consultation: Release of draft revised guidance documents on Post-Notice of Compliance (NOC) Changes - Quality, for stakeholder consultation [2021-08-06]
- Register of Innovative Drugs [2021-08-05]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-08-05]
- DPD Extracts [2021-08-03]
- Summary Basis of Decision (SBD) for AMGEVITA [2021-08-03]
- Summary Basis of Decision (SBD) for BRUKINSA [2021-08-03]
- Summary Basis of Decision (SBD) for ENHERTU [2021-08-03]
- Summary Basis of Decision (SBD) for REDESCA/REDESCA HP [2021-08-03]
- Summary Basis of Decision (SBD) for ZIRABEV [2021-08-03]
July
- Updated: Regulatory enrolment process (REP) [2021-07-30]
- Register of Innovative Drugs [2021-07-29]
- Updated List of Drugs for an Urgent Public Health Need [2021-07-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-07-27]
- Drug and medical device highlights 2020: Helping you maintain and improve your health [2021-07-27]
- Register of Innovative Drugs [2021-07-23]
- Notice: Clarifications Regarding Access to Restricted Drugs through the Special Access Program (SAP) [2021-07-23]
- Notice: Prescription Drug List (PDL): Multiple Additions [2021-07-23]
- Classification of Products under the Food and Drugs Act (F&DA) [2021-07-22]
- Updated: Guidance Document: Classification of Products at the Drug-Medical Device Interface [2021-07-22]
- Notice of Compliance (NOC) Data Extracts [2021-07-22]
- Qualifying Notice for Gavreto [2021-07-21]
- TPD/BRDD/NNHPD Annual Drug Submission Performance report - Fiscal Year 2020-2021 [2021-07-20]
- Summary Basis of Decision (SBD) for TISSUEBLUE [2021-07-20]
- Summary Basis of Decision (SBD) for NEXTSTELLIS [2021-07-20]
- Summary Basis of Decision (SBD) for MEKTOVI [2021-07-20]
- Summary Basis of Decision (SBD) for LUXTURNA [2021-07-20]
- Summary Basis of Decision (SBD) for HYRIMOZ [2021-07-20]
- Summary Basis of Decision (SBD) for BRAFTOVI [2021-07-20]
- Register of Innovative Drugs [2021-07-16]
- Product Monograph Brand Safety Updates - June 2021 [2021-07-16]
- Generic Submissions Under Review [2021-07-15]
- Submissions Under Review [2021-07-15]
- TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q4-2020-2021 [2021-07-13]
- Notice of Compliance (NOC) Data Extracts [2021-07-09]
- Register of Innovative Drugs [2021-07-09]
- Notice: Revision to the Guidance Document: Management of Drug Submissions and Applications [2021-07-07]
- Consultation: Release of Draft (Step 2) ICH Guidance: S12: Nonclinical Biodistribution Considerations for Gene Therapy Products [2021-07-05]
June
- DPD Extracts [2021-07-02]
- Health products international activities: Generic drug cluster [2021-06-28]
- Register of Innovative Drugs [2021-06-25]
- Notice of Compliance (NOC) Data Extracts [2021-06-25]
- Qualifying Notice for Retevmo [2021-06-24]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-06-24]
- Product Monograph Brand Safety Updates - May 2021 [2021-06-23]
- Generic Submissions Under Review [2021-06-22]
- Submissions Under Review [2021-06-22]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Agenda for June 23, 2021 [2021-06-18]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Summary of Findings and Advice for February 23rd, 2021 Virtual Meeting via Zoom [2021-06-18]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-06-16]
- Notice of Compliance (NOC) Data Extracts [2021-06-11]
- Consultation: Release of Draft (Step 2) ICH Guidance: S1B(R1): Addendum to the Guideline on Testing for Carcinogenicity of Pharmaceuticals [2021-06-10]
- Summary Basis of Decision (SBD) for DAYVIGO [2021-06-10]
- Summary Basis of Decision (SBD) for SUPEMTEK [2021-06-10]
- Summary Basis of Decision (SBD) for VYEPTI [2021-06-10]
- Qualifying Notice for Tepmetko [2021-06-08]
- Register of Innovative Drugs [2021-06-04]
- Notice: Release of ICH Q3C(R8): Maintenance: Impurities: Residual Solvents [2021-06-04]
- Notice of intent to amend: Prescription Drug List (PDL): Epinephrine (Topical Solution) [2021-06-04]
- Updated: Guidance Document: Patented Medicines (Notice of Compliance) Regulations [2021-06-02]
- DPD Extracts [2021-06-02]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-06-02]
- Updated: Drug Product Database (DPP) Terminology [2021-06-02]
- Updated: Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations [2021-06-01]
May
- Register of Innovative Drugs [2021-05-31]
- Updated: Notice to Stakeholders - Clarification of Requirements Under the Food and Drug Regulations When Conducting Clinical Research With Cannabis [2021-05-31]
- Notice: Phase II of the XML PM Project (Product Monograph in the Extensible Markup Language Format) [2021-05-28]
- Notice of Compliance (NOC) Data Extracts [2021-05-28]
- Notice: Prescription Drug List (PDL): Multiple Additions [2021-05-27]
- Generic Submissions Under Review [2021-05-27]
- Submissions Under Review [2021-05-27]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-05-26]
- Register of Innovative Drugs [2021-05-20]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-05-20]
- Product Monograph Brand Safety Updates - April 2021 [2021-05-18]
- Notice of Compliance (NOC) Data Extracts [2021-05-14]
- Summary Basis of Decision (SBD) for CORZYNA [2021-05-12]
- Summary Basis of Decision (SBD) for DOJOLVI [2021-05-12]
- Summary Basis of Decision (SBD) for INCRELEX [2021-05-12]
- Summary Basis of Decision (SBD) for NYVEPRIA [2021-05-12]
- Summary Basis of Decision (SBD) for TAVALISSE [2021-05-12]
- Consultation on the Issue identification paper: Drug-device combination products draft [2021-05-10]
- Register of Innovative Drugs [2021-05-07]
- DPD Extracts [2021-05-03 ]
- Updated: Regulatory enrolment process [2021-05-03]
April
- Register of Innovative Drugs [2021-04-30]
- Notice of Compliance (NOC) Data Extracts [2021-04-30]
- Qualifying Notice for Enhertu [2021-04-30]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Agenda for October 29 and 30, 2020 [2021-04-26]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Summary of Findings and Advice for October 29 and 30, 2020 Virtual Meeting [2021-04-26]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-04-23]
- Generic Submissions Under Review [2021-04-23]
- Submissions Under Review [2021-04-23]
- Notice of Consultation on the Prescription Drug List (PDL): Metamizole (dipyrone) [2021-04-23]
- Updated List of Drugs for an Urgent Public Health Need [2021-04-23]
- Product Monograph Brand Safety Updates - March 2021 [2021-04-20]
- Notice of Compliance (NOC) Data Extracts [2021-04-19]
- Updated List of Drugs for an Urgent Public Health Need [2021-04-16]
- Register of Innovative Drugs [2021-04-16]
- Project Orbis [2021-04-16]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2021-04-16]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-04-08]
- Notice of Compliance (NOC) Data Extracts [2021-04-01]
- DPD Extracts [2021-04-01]
March
- Notice: Prescription Drug List (PDL): Tramadol [2021-03-31]
- Updated: Guidance for completing the Drug Submission Application Form [2021-03-31]
- Summary Basis of Decision (SBD) for IDACIO [2021-03-31]
- Summary Basis of Decision (SBD) for INCLUNOX/INCLUNOX HP [2021-03-31]
- Summary Basis of Decision (SBD) for ZOLGENSMA [2021-03-31]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-03-29]
- Product Monograph Brand Safety Updates - February 2021 [2021-03-22]
- Submissions Under Review [2021-03-19]
- Generic Submissions Under Review [2021-03-19]
- Notice of Compliance (NOC) Data Extracts [2021-03-19]
- Register of Innovative Drugs [2021-03-19]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-03-17]
- Qualifying Notice for Keytruda [2021-03-17]
- TPD/BRDD/NNHPD Drug Submission Performance Quarterly Report for Q3-2020-2021 [2021-03-16]
- Consultation: Electronic media in prescription drug labelling draft guidance document [2021-03-12]
- Register of Innovative Drugs [2021-03-12]
- Summary Basis of Decision (SBD) for Inclunox/Inclunox HP [2021-03-10]
- Summary Basis of Decision (SBD) for Idacio [2021-03-10]
- Notice of Compliance (NOC) Data Extracts [2021-03-05]
- DPD Extracts [2021-03-01]
February
- Qualifying Notice for Opdivo [2021-02-26]
- Register of Innovative Drugs [2021-02-25]
- Product Monograph Brand Safety Updates - January 2021 [2021-02-25]
- Notice: Prescription Drug List (PDL): Vitamin D [2021-02-23]
- Scientific Advisory Committee on Health Products for Women (SAC-HPW): Agenda [2021-02-22]
- Generic Submissions Under Review [2021-02-19]
- Submissions Under Review [2021-02-19]
- Notice of Compliance (NOC) Data Extracts [2021-02-19]
- Summary Basis of Decision (SBD) for Anthim [2021-02-17]
- Summary Basis of Decision (SBD) for Trurapi [2021-02-17]
- Summary Basis of Decision (SBD) for Givlaari [2021-02-17]
- Register of Innovative Drugs [2021-02-11]
- Register of Innovative Drugs [2021-02-05]
- Notice of Compliance (NOC) Data Extracts [2021-02-05]
- Updated List of Drugs for an Urgent Public Health Need [2021-02-03]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-02-03]
- DPD Extracts [2021-02-01]
- Updated Register of Certificates of Supplementary Protection and Applications [2021-02-01]
January
- Regulatory innovation for health products [2021-01-29]
- Qualifying Notice for Verity-BCG [2021-01-29]
- Generic Submissions Under Review [2021-01-28]
- Submissions Under Review [2021-01-28]
- Summary Basis of Decision (SBD) for Noromby/Noromby HP [2021-01-28]
- Register of Innovative Drugs [2021-01-28]
- Register of Innovative Drugs [2021-01-25]
- Notice of Compliance (NOC) Data Extracts [2021-01-22]
- Updated: Filing submissions electronically [2021-01-12]
- Notice of Compliance (NOC) Data Extracts [2021-01-08]
- Product Monograph Brand Safety Updates - December 2020 [2021-01-08]
- Notice: Publication of the Guidance Document: Certificates of Supplementary Protection [2021-01-06]
- Notice to stakeholders: Harmonizing fludeoxyglucose (F-18 FDG) product monographs [2021-01-06]
- DPD Extracts [2021-01-04]
2020
December
- Register of Innovative Drugs [2020-12-31]
- Qualifying Notice for Keytruda [2020-12-30]
- Register of Innovative Drugs [2020-12-24]
- Notice of Compliance (NOC) Data Extracts [2020-12-23]
- Submissions Under Review [2020-12-23]
- Updated: Filing submissions electronically [2020-12-21]
- Summary Basis of Decision (SBD) for GalliaPharm [2020-12-21]
- Summary Basis of Decision (SBD) for Pfizer-BioNTech COVID-19 Vaccine [2020-12-21]
- Summary Basis of Decision (SBD) for Reblozyl [2020-12-21]
- Summary Basis of Decision (SBD) for Sarclisa [2020-12-21]
- Summary Basis of Decision (SBD) for Zeposia [2020-12-21]
- Notice: Prescription Drug List (PDL): Multiple additions [2020-12-21]
- Notice: Validation rules for regulatory transactions provided to Health Canada in the electronic Common Technical Document (eCTD) format [2020-12-16]
- Notice: Validation rules for regulatory transactions provided to Health Canada in the "non-eCTD electronic-only" format [2020-12-16]
- Notice: Validation Rules for Transactions Containing the Regulatory Enrollment Process (REP) Company XML File [2020-12-16]
- Consultation: ICH Reflection Paper: Proposed ICH Guideline Work to Advance Patient-Focused Drug Development [2020-12-16]
- Product Monograph Brand Safety Updates - November 2020 [2020-12-16]
- Adverse reactions, medical device incidents and health product recalls in Canada: 2019 summary report [2020-12-11]
- Notice of Compliance (NOC) Data Extracts [2020-12-11]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-12-10]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-12-04]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-12-02]
- DPD Extracts [2020-12-01]
November
- TPD/BRDD/NNHPD Drug Submission Quarterly Report for January - September 2020 [2020-11-30]
- Interim Order Respecting Drug Shortages (Safeguarding the Drug Supply): Notice [2020-11-28]
- Interim Order Respecting Drug Shortages (Safeguarding the Drug Supply) [2020-11-28]
- Register of Innovative Drugs [2020-11-27]
- Notice of Compliance (NOC) Data Extracts [2020-11-27]
- Generic Submissions Under Review [2020-11-25]
- Submissions Under Review [2020-11-25]
- Updated List of Drugs for an Urgent Public Health Need [2020-11-23]
- Product Monograph Brand Safety Updates - October 2020 [2020-11-17]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-11-16]
- Register of Innovative Drugs [2020-11-13]
- Notice of Compliance (NOC) Data Extracts [2020-11-13]
- Notice of clarification to drug manufacturers and sponsors: Canadian-specific considerations in risk management plans [2020-11-12]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-11-10]
- Summary Basis of Decision (SBD) for Firdapse [2020-11-06]
- Summary Basis of Decision (SBD) for Inrebic [2020-11-06]
- Summary Basis of Decision (SBD) for Mar-Trientine [2020-11-06]
- Summary Basis of Decision (SBD) for Xenleta [2020-11-06]
- DPD Extracts [2020-11-02]
- Guidance document: Product Monograph [2020-11-01]
- Product Monograph master template [2020-11-01]
- Product Monographs: Frequently asked questions [2020-11-01]
October
- Notice of Compliance (NOC) Data Extracts [2020-10-30]
- Summary Basis of Decision (SBD) for Polivy [2020-10-30]
- Summary Basis of Decision (SBD) for Tomvi [2020-10-30]
- Summary Basis of Decision (SBD) for Tukysa [2020-10-30]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-10-28]
- Validation Rules for Transactions Containing the Regulatory Enrolment Process (REP) Company XML File [2020-10-26]
- Register of Innovative Drugs [2020-10-23]
- Summary Basis of Decision (SBD) for Ruzurgi [2020-10-23]
- Product Monograph Brand Safety Updates - September 2020 [2020-10-22]
- Generic Submissions Under Review [2020-10-20]
- Submissions Under Review [2020-10-20]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-10-20]
- Notice of Compliance (NOC) Data Extracts [2020-10-16]
- Notice: Interim Implementation of International Council for Harmonisation (ICH) Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management [2020-10-09]
- Register of Innovative Drugs [2020-10-08]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2020-10-08]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-10-07]
- Summary Basis of Decision (SBD) for Riximyo [2020-10-02]
- Summary Basis of Decision (SBD) for Qinlock [2020-10-02]
- Summary Basis of Decision (SBD) for Piqray [2020-10-02]
- Summary Basis of Decision (SBD) for Inqovi [2020-10-02]
- Summary Basis of Decision (SBD) for Ibsrela [2020-10-02]
- Summary Basis of Decision (SBD) for Enspryng [2020-10-02]
- Register of Innovative Drugs [2020-10-02]
- Notice of Compliance (NOC) Data Extracts [2020-10-02]
- DPD Extracts [2020-10-01]
September
- Release of Draft (Step 2) ICH Guidance: Q3D(R2): Impurities: Elemental Impurities [2020-09-29]
- Register of Innovative Drugs [2020-09-25]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-09-24]
- Summary Basis of Decision (SBD) for Enspryng [2020-09-24]
- Summary Basis of Decision (SBD) for Riximyo [2020-09-24]
- Summary Basis of Decision (SBD) for Ibsrela [2020-09-24]
- Summary Basis of Decision (SBD) for Piqray [2020-09-24]
- Notice: Validation rules for regulatory transactions provided to Health Canada in the "non-eCTD electronic-only" format [2020-09-21]
- Notice - Validation rules for regulatory transactions submitted to Health Canada in the electronic Common Technical Document (eCTD) format [2020-09-21]
- Consultation: Release of Draft (Step 2) ICH Guidance: E14/S7B: Questions & Answers: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential [2020-09-21]
- Submissions Under Review [2020-09-21]
- Generic Submissions Under Review [2020-09-21]
- Notice to Stakeholders - Clarification of Requirements under the Food and Drug Regulations when Conducting Clinical Research with Cannabis [2020-09-18]
- Notice of Compliance (NOC) Data Extracts [2020-09-18]
- Product Monograph Brand Safety Updates - August 2020 [2020-09-16]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-09-14]
- Register of Innovative Drugs [2020-09-11]
- Notice: Prescription Drug List (PDL): Multiple additions [2020-09-08]
- Notice of Compliance (NOC) Data Extracts [2020-09-04]
- Statistical Report 2019/2020 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection and Certificates of Supplementary Protection [2020-09-02]
August
- DPD Extracts [2020-09-01]
- Notice - Release of ICH M9: Biopharmaceutics Classification System (BCS) Based Biowaivers [2020-08-26]
- Notice - Release of ICH M9 Questions & Answers: Biopharmaceutics Classification System (BCS) Based Biowaivers [2020-08-26]
- Updated List of Drugs for an Urgent Public Health Need [2020-08-26]
- Summary Basis of Decision (SBD) for Beovu [2020-08-25]
- Summary Basis of Decision (SBD) for Nivestym [2020-08-25]
- Summary Basis of Decision (SBD) for Odomzo [2020-08-25]
- Summary Basis of Decision (SBD) for Ruxience [2020-08-25]
- Summary Basis of Decision (SBD) for Veklury [2020-08-25]
- Summary Basis of Decision (SBD) for Ziextenzo [2020-08-25]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-08-24]
- Nitrosamine impurities in medications [2020-08-24]
- Notice of Compliance (NOC) Data Extracts [2020-08-21]
- Notice - Prescription Drug List: Vitamin D [2020-08-19]
- Generic Submissions Under Review [2020-08-19]
- Submission Under Review [2020-08-19]
- Register of Innovative Drugs [2020-08-18]
- Notice - Release of ICH S11: Nonclinical Safety Testing in Support of Development of Paediatric Medicines [2020-08-17]
- Product Monograph Brand Safety Updates - July 2020 [2020-08-12]
- Summary Basis of Decision (SBD) for Daurismo [2020-08-11]
- Summary Basis of Decision (SBD) for Mylotarg [2020-08-11]
- Summary Basis of Decision (SBD) for Rozlytrek [2020-08-11]
- Notice - Release of ICH S5(R3): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility [2020-08-10]
- Notice of Compliance (NOC) Data Extracts [2020-08-07]
- Statement on the classification of insulin products and duration of action: Notice to stakeholders [2020-08-06]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-08-05]
- DPD Extracts [2020-08-04]
July
- Notice of Compliance (NOC) Data Extracts [2020-07-31]
- Register of Innovative Drugs [2020-07-29]
- TPD/BRDD/NNHPD Annual Drug Submission Performance report - Fiscal Year 2019-2020 [2020-07-28]
- Submission Under Review [2020-07-28]
- Notice of Compliance (NOC) Data Extracts [2020-07-27]
- Register of Innovative Drugs [2020-07-24]
- Submission Under Review [2020-07-24]
- Generic Submissions Under Review [2020-07-23]
- Notice - Release of ICH E9(R1): Defining the Appropriate Estimand for a Clinical Trial/ Sensitivity Analyses [2020-07-21]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-07-21]
- Register of Innovative Drugs [2020-07-17]
- Summary Basis of Decision (SBD) for Ajovy [2020-07-14]
- Summary Basis of Decision (SBD) for Kanjinti [2020-07-14]
- Summary Basis of Decision (SBD) for Nubeqa [2020-07-14]
- Summary Basis of Decision (SBD) for Vocabria/Cabenuva [2020-07-14]
- Register of Innovative Drugs [2020-07-13]
- Notice of Compliance (NOC) Data Extracts [2020-07-10]
- Notice: Prescription Drug List (PDL): Multiple additions [2020-07-10]
- Product Monograph Brand Safety Updates - June 2020 [2020-07-10]
- Release of draft (step 2) ICH guidance: M7(R2): Assessment and Control of DNA Reactive (mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [2020-07-07]
- Mid-year update: Drugs and medical devices approved in 2020 [2020-07-08]
- Notice - Confirmation of the Mandatory use of the Regulatory Enrolment Process (REP) as of October 1, 2020 [2020-07-06]
- DPD Extracts [2020-07-02]
June
- Release of draft (Step 2) ICH guidance: Q3C(R8): Impurities: Residual solvents [2020-06-30]
- Summary Basis of Decision (SBD) for Ajovy [2020-06-30]
- Summary Basis of Decision (SBD) for Kanjinti [2020-06-30]
- Summary Basis of Decision (SBD) for Vocabria/Cabenuva [2020-06-30]
- Register of Innovative Drugs [2020-06-29]
- Notice of Compliance (NOC) Data Extracts [2020-06-26]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-06-23]
- Generic Submissions Under Review [2020-06-23]
- Submissions Under Review [2020-06-23]
- Register of Innovative Drugs [2020-06-19]
- Summary Basis of Decision (SBD) for Avsola [2020-06-19]
- Summary Basis of Decision (SBD) for Cablivi [2020-06-19]
- Summary Basis of Decision (SBD) for Vyndaqel [2020-06-19]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-06-18]
- Register of Innovative Drugs [2020-06-15]
- Notice of Compliance (NOC) Data Extracts [2020-06-12]
- Product Monograph Brand Safety Updates - May 2020 [2020-06-11]
- Register of Innovative Drugs [2020-06-05]
- Tecentriq: Qualifying Notice Amendment [2020-06-02]
- DPD Extracts [2020-06-01]
May
- Updated Register of Certificates of Supplementary Protection and Applications [2020-05-29]
- Notice of Compliance (NOC) Data Extracts [2020-05-29]
- Drug and medical device highlights 2019: Helping you maintain and improve your health [2020-05-28]
- Notice: Expansion of the medical device Regulatory Enrolment Process (REP) pilot and the scope for transactions sent via the Common Electronic Submissions Gateway (CESG) [2020-05-26]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-05-25]
- Summary Basis of Decision (SBD) for Herzuma [2020-05-22]
- Summary Basis of Decision (SBD) for Mayzent [2020-05-22]
- Summary Basis of Decision (SBD) for Osnuvo [2020-05-22]
- Summary Basis of Decision (SBD) for Rinvoq [2020-05-22]
- Summary Basis of Decision (SBD) for Vascepa [2020-05-22]
- Summary Basis of Decision (SBD) for Xofluza [2020-05-22]
- Notice of Compliance (NOC) Data Extracts [2020-05-15]
- Submissions Under Review [2020-05-14]
- Generic Submissions Under Review [2020-05-14]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-05-12]
- Product Monograph Brand Safety Updates - April 2020 [2020-05-12]
- Register of Innovative Drugs [2020-05-08]
- DPD Extracts [2020-05-01]
- Register of Innovative Drugs [2020-05-01]
April
- Guidance Document on the Distribution of Drugs as Samples [2020-04-29]
- List incorporated by reference [2020-04-29]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-04-29]
- Updated List of Drugs for an Urgent Public Health Need [2020-04-24]
- Register of Innovative Drugs [2020-04-24]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-04-21]
- Summary Basis of Decision (SBD) for Aklief [2020-04-20]
- Summary Basis of Decision (SBD) for Galli Eo [2020-04-20]
- Summary Basis of Decision (SBD) for Intrarosa [2020-04-20]
- Summary Basis of Decision (SBD) for Lokelma [2020-04-20]
- Summary Basis of Decision (SBD) for Netspot [2020-04-20]
- Summary Basis of Decision (SBD) for Trazimera [2020-04-20]
- Summary Basis of Decision (SBD) for Ultomiris [2020-04-20]
- Summary Basis of Decision (SBD) for Xospata [2020-04-20]
- Notice of Compliance (NOC) Data Extracts [2020-04-17]
- Product Monograph Brand Safety Updates - March 2020 [2020-04-17]
- Submissions Under Review [2020-04-17]
- Generic Submissions Under Review [2020-04-16]
- Register of Innovative Drugs [2020-04-14]
- Guidance Document - Preparation of Regulatory Activities in eCTD Format [2020-04-14]
- Certificate of Supplementary Protection (CSP) Application Form [2020-04-09]
- Notice of Compliance (NOC) Data Extracts [2020-04-06]
- Funding and Fees [2020-04-01]
- DPD Extracts [2020-04-01]
- Updated List of Drugs for an Urgent Public Health Need [2020-04-01]
- Guidance Document: Drug Identification Numbers for Schedule C Drugs (Radiopharmaceuticals and Kits) [2020-04-01]
March
- Register of Innovative Drugs [2020-03-31]
- Submissions Under Review [2020-03-30]
- Guidance Document Questions and Answers: Plain Language Labelling Regulations for Non-prescription Drugs [2020-03-31]
- Notice: Mandatory use of the Regulatory Enrolment Process (REP) as of October 1, 2020 [2020-03-30]
- Post-Notice of Compliance (NOC) Changes: Framework Document (Pharmaceutical, biologic and radiopharmaceutical drugs for human use only) [2020-03-30]
- Generic Submissions Under Review [2020-03-30]
- Notice - Notification of Safety Labelling Changes to the Product Monographs of Pharmaceutical Drug Products [2020-03-30]
- Product Monograph Brand Safety Updates - February 2020 [2020-03-18]
- Register of Innovative Drugs [2020-03-26]
- Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs [2020-03-26]
- Register of Innovative Drugs [2020-03-23]
- Update: Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2020-03-20]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2020-03-20]
- Guidance for Completing the Drug Submission Application Form (applicable on or after April 1st, 2019) [2020-03-20]
- Notice of Compliance (NOC) Data Extracts [2020-03-20]
- How to Pay Fees for Health Products [2019-03-20]
- Notice: Expedited Review of Health Product Submissions and Applications to address COVID-19 [2020-03-18]
- Register of Innovative Drugs [2020-03-13]
- TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q3-2019-2020
- Updated Register of Certificates of Supplementary Protection and Applications [2020-03-10]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines [2020-03-05]
- Notice of Compliance (NOC) Extracts [2020-03-06]
- Register of Innovative Drugs [2020-03-06]
- Register of Innovative Drugs [2020-03-05]
- DPD Extracts [2020-03-03]
- Rozlytrek - Notice of Compliance with Conditions - Qualifying Notice [2020-03-03]
February
- Notice of Compliance (NOC) Data Extracts [2020-02-28]
- Register of Innovative Drugs [2020-02-27]
- Notice: Release of Draft Guidance Document for Consultation: Comparative Pharmacokinetic Studies for Orally Inhaled Products [2020-02-26]
- Generic Submissions Under Review [2020-02-24]
- Submissions Under Review [2020-02-24]
- Notice of Compliance (NOC) Data Extracts [2020-02-21]
- Notice: Implementation of eCTD for Clinical Trial Regulatory Activities [2020-02-19]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-02-17]
- Notice of Compliance (NOC) Data Extracts [2020-02-14]
- Register of Innovative Drugs [2020-02-14]
- Product Monograph Brand Safety Updates - January 2020 [2020-02-14]
- Notice: Prescription Drug List (PDL): Multiple Additions [2020-02-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-02-10]
- Notice of Compliance (NOC) Data Extracts [2020-02-07]
- Summary Basis of Decision - Balversa [2020-02-05]
- Summary Basis of Decision - Nerlynx [2020-02-05]
- Summary Basis of Decision - Trulance [2020-02-05]
- DPD Extracts [2020-02-03]
January
- Notice of Compliance (NOC) Data Extracts [2020-01-31]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-01-29]
- Summary Basis of Decision - Calquence [2020-01-28]
- Summary Basis of Decision - Emgality [2020-01-28]
- Summary Basis of Decision - Talzenna [2020-01-28]
- Summary Basis of Decision - Tibella [2020-01-28]
- Summary Basis of Decision - Vitrakvi [2020-01-28]
- Register of Innovative Drugs [2020-01-27]
- Notice of Compliance (NOC) Data Extracts [2020-01-24]
- Product Monograph Brand Safety Updates - December 2019 [2020-01-24]
- Notice of Compliance (NOC) Data Extracts [2020-01-17]
- Notice: Product Monograph Implementation Plans [2020-01-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2020-01-10]
- Notice of Compliance (NOC) Data Extracts [2020-01-10]
- Register of Innovative Drugs [2020-01-10]
- Notice of Compliance (NOC) Data Extracts [2020-01-06]
- Register of Innovative Drugs [2020-01-06]
- Summary Basis of Decision - Dacogen [2020-01-06]
- Summary Basis of Decision - Esperoct [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Cerdelga [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Eucrisa [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Fetzima [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Alecensaro [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Iclusig [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Imbruvica [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Kisqali [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Genvoya [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Lenvima [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Giotrif [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Mictoryl [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Monoferric [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Olumiant [2020-01-06]
- Post-Authorization Activity Table (PAAT) - Maviret [2020-01-06]
- DPD Extracts [2020-01-02]
2019
December
- Notice of Compliance with Conditions - Qualifying Notice for Blincyto [2019-12-31]
- Notice of Compliance (NOC) Data Extracts [2019-12-30]
- Updated List of Drugs for an Urgent Public Health Need [2019-12-23]
- Notice of Compliance (NOC) Data Extracts [2019-12-20]
- Register of Innovative Drugs [2019-12-20]
- TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q2-2019-2020 [2019-12-20]
- Product Monograph Brand Safety Updates - November 2019 [2019-12-20]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-12-13]
- Generic Submissions Under Review [2019-12-13]
- Notice of Compliance (NOC) Data Extracts [2019-12-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-12-10]
- Summary Basis of Decision - Evenity [2019-12-10]
- Summary Basis of Decision - Zejula [2019-12-10]
- Summary Basis of Decision - Zirabev [2019-12-10]
- Post-Authorization Activity Table (PAAT) - Biktarvy [2019-12-10]
- Post-Authorization Activity Table (PAAT) - Blexten [2019-12-10]
- Post-Authorization Activity Table (PAAT) - Bystolic [2019-12-10]
- Post-Authorization Activity Table (PAAT) - Erleada [2019-12-10]
- Notice of Compliance (NOC) Data Extracts [2019-12-06]
- Register of Innovative Drugs [2019-12-06]
- Final Record of Decisions June 5, 2018 Meeting: Canadian Generic Pharmaceutical Association (CGPA) [2019-12-04]
- Final Record of Decisions December 4, 2018 Meeting: Canadian Generic Pharmaceutical Association (CGPA) [2019-12-04]
- Final Record of Decisions October 2, 2018 Meeting: Groupement provincial de l'industrie du médicament (GPIM) [2019-12-04]
- Final Record of Decisions May 10, 2018 Meeting: Innovative Medicines Canada (IMC) [2019-12-04]
- Final Record of Decisions November 13, 2018 Meeting: Innovative Medicines Canada (IMC) [2019-12-04]
- Final Record of Decisions May 24, 2018 Meeting: Canada's Medical Technology Companies (MEDEC) [2019-12-04]
- Final Record of Decisions November 8, 2018 Meeting: Canada's Medical Technology Companies (MEDEC) [2019-12-04]
- Generic Submissions Under Review [2019-12-03]
- Submissions Under Review [2019-12-03]
- DPD Extracts [2019-12-02]
November
- Notice: Prescription Drug List (PDL): Multiple additions [2019-11-29]
- Notice - Update to Clinical Trial Site Information Form [2019-11-29]
- Notice of Compliance (NOC) Data Extracts [2019-11-29]
- Notice of Compliance (NOC) Data Extracts [2019-11-22]
- Updated List of Drugs for an Urgent Public Health Need [2019-11-21]
- Notice of Compliance with Conditions - Qualifying Notice for Balversa [2019-11-18]
- Notice of Compliance (NOC) Data Extracts [2019-11-15]
- Register of Innovative Drugs [2019-11-15]
- Summary Basis of Decision - Ogivri [2019-11-15]
- Summary Basis of Decision - Onpattro [2019-11-15]
- Summary Basis of Decision - Skyrizi [2019-11-15]
- Summary Basis of Decision - Verzenio [2019-11-15]
- Summary Basis of Decision - Vizimpro [2019-11-15]
- Product Monograph Brand Safety Updates - October 2019 [2019-11-15]
- Notice of Compliance (NOC) Data Extracts [2019-11-08]
- Updated List of Drugs for an Urgent Public Health Need [2019-11-06]
- DPD Extracts [2019-11-01]
- Register of Innovative Drugs [2019-11-01]
- Notice of Compliance (NOC) Data Extracts [2019-11-01]
October
- Updated List of Drugs for an Urgent Public Health Need [2019-10-30]
- Submissions Under Review [2019-10-30]
- Generic Submissions Under Review [2019-10-30]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-10-29]
- Notice of Compliance (NOC) Data Extracts [2019-10-25]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-10-24]
- Register of Innovative Drugs [2019-10-21]
- Register of Innovative Drugs [2019-10-18]
- Notice of Compliance (NOC) Data Extracts [2019-10-18]
- Product Monograph Brand Safety Updates - September 2019 [2019-10-16]
- Notice of Compliance (NOC) Data Extracts [2019-10-11]
- Register of Innovative Drugs [2019-10-10]
- Notice of Compliance with Conditions - Qualifying Notice for Lenvima [2019-10-09]
- Notice: Prescription Drug List (PDL): Multiple additions [2019-10-07]
- Register of Innovative Drugs [2019-10-04]
- DPD Extracts [2019-10-04]
- Notice of Compliance (NOC) Data Extracts [2019-10-04]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-10-01]
- DPD Extracts [2019-10-01]
September
- Notice of Compliance (NOC) Data Extracts [2019-09-27]
- Updated List of Drugs for an Urgent Public Health Need [2019-09-25]
- Notice of Compliance (NOC) Data Extracts [2019-09-20]
- Register of Innovative Drugs [2019-09-20]
- Updated List of Drugs for an Urgent Public Health Need [2019-09-18]
- Submissions Under Review [2019-09-16]
- Generic Submissions Under Review [2019-09-16]
- Notice of Compliance (NOC) Data Extracts [2019-09-13]
- Updated List of Drugs for an Urgent Public Health Need [2019-09-13]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-09-12]
- Summary Basis of Decision (SBD) for Idhifa [2019-09-10]
- Summary Basis of Decision (SBD) for Libtayo [2019-09-10]
- Summary Basis of Decision (SBD) for Yescarta [2019-09-10]
- Updated List of Drugs for an Urgent Public Health Need [2019-09-09]
- Product Monograph Brand Safety Updates - August 2019 [2019-09-09]
- Register of Innovative Drugs [2019-09-06]
- Notice of Compliance (NOC) Data Extracts [2019-09-06]
- TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q1-2019-2020 [2019-09-04]
- DPD Extracts [2019-09-04]
August
- Register of Innovative Drugs [2019-08-30]
- Notice of Compliance (NOC) Data Extracts [2019-08-30]
- Register of Innovative Drugs [2019-08-29]
- The Regulatory Enrolment Process (REP) is now in production. All regulatory transactions for human drugs, pursuant to Division 1 and 8 of the Food and Drug Regulations are encouraged use REP with regulatory transactions prepared in both eCTD and non-eCTD formats. The REP information page has been updated to include the REP Guidance Document, REP templates as well as information on REP pilots coming up for Veterinary Drugs and Clinical Trials. [2019-08-28]
- Blincyto - Notice of Compliance with Conditions - Qualifying Notice [2019-08-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-08-27]
- Biosimilar biologic drugs in Canada: Fact Sheet [2019-08-27]
- Summary Basis of Decision (SBD) for LORBRENA [2019-08-27]
- Summary Basis of Decision (SBD) for ONSTRYV [2019-08-27]
- Summary Basis of Decision (SBD) for OXERVATE [2019-08-27]
- Summary Basis of Decision (SBD) for TRUXIMA [2019-08-27]
- Health Canada approves updates to Mifegymiso prescribing information: Ultrasound no longer mandatory [2019-08-23]
- Submissions Under Review [2019-08-20]
- Biopharmaceutics Classification System (BCS) based biowaiver evaluation template [2019-08-23]
- Notice of Compliance (NOC) Data Extracts [2019-08-23]
- Generic Submissions Under Review [2019-08-23]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-08-19]
- Notice of Compliance (NOC) Data Extracts [2019-08-16]
- Updated List of Drugs for an Urgent Public Health Need [2019-08-15]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-08-14]
- Master File (MF) Application Fee Form for Human Drugs [2019-08-14]
- Product Monograph Brand Safety Updates - July 2019 [2019-08-13]
- Radiopharmaceuticals, Kits, and Generators: Submission Information for Schedule C Drugs - Guidance document [2019-08-13]
- TPD, BGTD and NNHPD Quarterly Drug Submission Performance Report for Q1-2019-2020 [2019-08-13]
- Release of the revised Guidance Document: Post-Notice of Compliance (NOC) Changes - Safety and Efficacy [2019-08-12]
- Notice of Consultation on the Prescription Drug List (PDL): Epinephrine chloride (topical solution) [2019-08-12]
- Register of Innovative Drugs [2019-08-12]
- Notice of Compliance (NOC) Data Extracts [2019-08-09]
- Revisions to the Guidance Document: Questions & Answers: Plain Language Labelling Regulations for Prescription Drugs [2019-08-08]
- Register of Innovative Drugs [2019-08-06]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines Update [2019-08-06]
- Notice of Compliance (NOC) Data Extracts [2019-08-02]
- DPD Extracts [2019-08-01]
July
- Release of the revised Post-Notice of Compliance (NOC) Changes - Quality Guidance [2019-07-31]
- Release of the revised Notice regarding the Post-Notice of Compliance (NOC) Changes- Notices of Change: Level III Form [2019-07-31]
- Register of Innovative Drugs [2019-07-26]
- Notice of Compliance (NOC) Data Extracts [2019-07-26]
- Revisions to the Guidance Document: Management of Drug Submissions and Applications [2019-07-25]
- Labels and Packages Certification Form for Prescription Products [2019-07-25]
- Generic Submissions Under Review [2019-07-22]
- Submissions Under Review [2019-07-22]
- ICH Global Meeting on ICH E8(R1) Guideline on General Considerations for Clinical Trials [2019-07-19]
- Notice of Compliance (NOC) Data Extracts [2019-07-19]
- Agile regulations for advanced therapeutic products and clinical trials [2019-07-18]
- Organisation and Document Placement for Canadian Module 1 of the Common Technical Document (CTD) Structure [2019-07-17]
- Statistical Report 2018 / 2019 - Patented Medicines (Notice of Compliance) Regulations, Data Protection (C.08.004.1 of the Food and Drug Regulations) and Certificates of Supplementary Protection [2019-07-16]
- Qualifying Notice for Vitrakvi [2019-07-16]
- Register of Innovation Drugs [2019-07-12]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-07-12]
- Notice of Compliance (NOC) Data Extracts [2019-07-12]
- Summary Basis of Decision (SBD) for BIOTHRAX [2019-07-10]
- Summary Basis of Decision (SBD) for VONVENDI [2019-07-10]
- Summary Basis of Decision (SBD) for DEMYLOCAN [2019-07-10]
- Product Monograph Brand Safety Updates - June 2019 [2019-07-10]
- Notice: Guidance on the Clinical Assessment of Abuse Liability for Drugs with Central Nervous System Activity [2019-07-08]
- Notice: Prescription Drug List (PDL): Multiple Additions [2019-07-08]
- Notice of Compliance (NOC) Data Extracts [2019-07-05]
- Enabling advanced therapeutic products and modernizing the regulation of clinical trials [2019-07-02]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-07-02]
- Notice: Regulatory Enrolment Process (REP) Pilot for Veterinary Drugs [2019-07-02]
- DPD Extracts [2019-07-02]
June
- Register of Innovative Drugs [2019-06-28]
- Notice of Compliance (NOC) Data Extracts [2019-06-28]
- Notice: Revisions to the Guidance Document: Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs [2019-06-28]
- Drug and medical device highlights 2018: Helping you maintain and improve your health [2019-06-27]
- Summary Basis of Decision (SBD) for BRINEURA [2019-06-27]
- Summary Basis of Decision (SBD) for FULPHILA [2019-06-27]
- Summary Basis of Decision (SBD) for LUTATHERA [2019-06-27]
- Consultation on: Draft Guidance: Canadian Module 1 Technical Implementation Guide for the Electronic Common Technical Document (eCTD) v4.0 Format [2019-06-26]
- Mandatory reporting requirements for hospitals [2019-06-26]
- Submissions Under Review [2019-06-24]
- Generic Submissions Under Review [2019-06-24]
- Notice - Regulatory Enrolment Process (REP) implementation and expansion of the scope for the Common Electronic Submissions Gateway (CESG) [2019-06-20]
- Notice of Compliance (NOC) Data Extracts [2019-06-21]
- Notice - New regulatory activity types for filing to the Marketed Health Products Directorate (MHPD) [2019-06-21]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-06-20]
- Updated List of Drugs for an Urgent Public Health Need [2019-06-19]
- Register of Innovative Drugs [2019-06-17]
- Notice of Compliance (NOC) Data Extracts [2019-06-17]
- TPD/BGTD/NNHPD Quarterly Drug Submission Performance report for January - March 2019 & TPD/BGTD/NNHPD Annual Drug Submission Performance report for FY2018-2019 [2019-05-31]
- Notice of Compliance (NOC) Data Extracts [2019-06-07]
- Updated List of Drugs for an Urgent Public Health Need [2019-06-05]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-06-04]
- Updated Product Monograph Template - Schedule D and Schedule D Biosimilar Biologic Drug [2019-06-04]
- DPD Extracts [2019-06-03]
May
- Q3D(R1): Guideline for Elemental Impurities [2019-05-31]
- Notice of Compliance (NOC) Data Extracts [2019-05-31]
- Updated List of Drugs for an Urgent Public Health Need [2019-05-28]
- Notice of Compliance (NOC) Data Extracts [2019-05-24]
- Summary Basis of Decision (SBD) for Crysvita [2019-05-24]
- Summary Basis of Decision (SBD) for Folotyn [2019-05-24]
- Summary Basis of Decision (SBD) for Unituxin[2019-05-24]
- Summary Basis of Decision (SBD) for Veltassa [2019-05-24]
- Scientific Advisory Committee on Oncology Therapies - Meeting announcement and Agenda for June 14, 2019 [2019-05-22]
- Notice of Consultation on the Prescription Drug List: Vitamin D [2019-05-22]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-05-21]
- Notice of Compliance (NOC) Data Extracts [2019-05-17]
- Submissions Under Review [2019-05-16]
- Generic Submissions Under Review [2019-05-15]
- Final Report: Fees for Drugs and Medical Devices [2019-05-15]
- Performance Standards for the Fees in Respect of Drugs and Medical Devices Order [2019-05-15]
- Updated Guidance Document: Certificates of Supplementary Protection & Updated Certificate of Supplementary Protection (CSP) Application Form [2019-05-15]
- Structured Format for Product Monographs [2019-05-15]
- Scientific/Expert Advisory Committee: Health Products for Women - Summary of Affiliations and Interests [2019-05-15]
- Product Monograph Brand Safety Updates - April 2019 [2019-05-14]
- Product Monograph Brand Safety Updates - May 2019 [2019-05-12]
- Draft Guidance Document for Industry and Practitioners on the Special Access Program (SAP) for Drugs [2019-05-10]
- Draft Guidance: Public or Canadian Armed Forces Health Emergencies - Drugs for Immediate Use or Stockpiling [2019-05-10]
- Notice of Compliance (NOC) Data Extracts [2019-05-10]
- Regulatory Decision Summary for Modification of MSM Blood Donor Deferral [2019-05-07]
- Product Monograph Brand Safety Updates - March 2019 [2019-05-06]
- Keytruda - Notice of Compliance with Conditions - Qualifying Notice [2019-05-07]
- Register of Innovative Drugs [2019-05-03]
- Notice of Compliance (NOC) Data Extracts [2019-05-03]
- Release of Guidance Document: Regulatory requirements for Drug Identification Numbers (DINs) [2019-05-03]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-05-03]
- Updated List of Drugs for an Urgent Public Health Need [2019-05-03]
- DPD Extracts [2019-05-01]
April
- Generic Submissions Under Review [2019-04-30]
- Submissions Under Review [2019-04-30]
- Updated List of Drugs for an Urgent Public Health Need [2019-04-30]
- Scientific Advisory Committee on Health Products for Women - Meeting Announcement - May 16-17, Membership List and Biographies [2019-04-26]
- Notice of Compliance (NOC) Data Extracts [2019-04-26]
- Notice of Consultation on the Prescription Drug List: Tramadol [2019-04-24]
- Notice of Compliance (NOC) Data Extracts [2019-04-18]
- Register of Innovative Drugs [2019-04-18]
- Post-Authorization Activity Table (PAAT) for Mifegymiso [2019-04-16]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-04-16]
- Notice - Release of ICH E17: Multi-Regional Clinical Trials [2019-04-12]
- Notice of Compliance (NOC) Data Extracts [2019-04-12]
- Notice of Intent - Structured Product Monograph [2019-04-10]
- Consultation on: Draft Guidance Document Identifying and Labelling Medicinal Ingredients and Draft Guidance Document Generic Drug Equivalence: Medicinal Ingredients [2019-04-08]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-04-08]
- Register of Innovative Drugs [2019-04-05]
- Notice of Compliance (NOC) Data Extracts [2019-04-05]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-04-04]
- Notice: Health Canada and United States Food and Drug Administration Joint Public Consultation on International Council on Harmonisation Guidelines [2019-04-03]
- Notice: Release of the guidance document E6(R2): Good Clinical Practice [2019-04-03]
- Updated List of Drugs for an Urgent Public Health Need [2019-04-03]
- Notice: For Consultation: Draft (Step 2) ICH Guidance: M10 Bioanalytical Validation Method [2019-04-03]
- Lorbrena - Notice of Compliance with Conditions - Qualifying Notice [2019-04-02]
- DPD Extracts [2019-04-01]
March
- Notice of Compliance (NOC) Data Extracts [2019-03-29]
- Notice: Prescription Drug List (PDL): Multiple additions [2019-03-28]
- Updated: Notice re: Validation rules for regulatory transactions provided to Health Canada in the electronic Common Technical Document (eCTD) format [2019-03-29]
- Updated List of Drugs for an Urgent Public Health Need [2019-03-27]
- Notice of Compliance (NOC) Data Extracts [2019-03-26]
- Filing Submissions Electronically [2019-03-25]
- Updated Fee Forms [2019-03-25]
- Register of Innovative Drugs [2019-03-22]
- What we heard: A summary of scanning and consultations on what's next for health product regulation
- Submissions Under Review [2019-03-18]
- Generic Submissions Under Review [2019-03-15]
- Notice of Compliance (NOC) Data Extracts [2019-03-15]
- Notice to Stakeholders: Updates to the Opioid Patient Information Handout [2019-03-15]
- Clinical information on drugs and health products
- Updated Register of Certificates of Supplementary Protection and Applications [2019-03-11]
- Product Monograph Brand Safety Updates - February 2019 [2019-03-11]
- Notice of Compliance (NOC) Data Extracts [2019-03-11]
- Stop illegal marketing of drugs and devices
- Updated Register of Certificates of Supplementary Protection and Applications[2019-03-05]
- Notice: Prescription Drug List (PDL): Multiple additions [2019-03-05]
February
- DPD Extracts [2019-03-01]
- Product Monograph Brand Safety Updates - January 2019 [2019-02-28]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-02-27]
- Guidance Document: Master Files (MFs) - Procedures and Administrative Requirements [2023-06-26]
- TPD Quarterly Drug Submission Performance report for October - December 2018 [2019-02-25]
- Regulatory Decision Summary for APTIOM [2019-02-25]
- Summary Basis of Decision (SBD) for CABOMETYX [2019-02-25]
- Regulatory Decision Summary for ERELZI [2019-02-25]
- Post-Authorization Activity Table (PAAT) for Fibristal [2019-02-25]
- Post-Authorization Activity Table (PAAT) for Harvoni [2019-02-25]
- Post-Authorization Activity Table (PAAT) for Holkira Pak [2019-02-25]
- Summary of Cancellation for Innohep Control number 199839 [2019-02-25]
- Post-Authorization Activity Table (PAAT) for Keytruda [2019-02-25]
- Summary Basis of Decision (SBD) for KYMRIAH [2019-02-25]
- Post-Authorization Activity Table (PAAT) for Mekinist [2019-02-25]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-02-22]
- Generic Submissions Under Review [2019-02-22]
- Notice of Compliance (NOC) Data Extracts [2019-02-22]
- Register of Innovative Drugs [2019-02-21]
- Submissions Under Review [2019-02-21]
- Register of Innovative Drugs [2019-02-15]
- Notice of Compliance (NOC) Data Extracts [2019-02-15]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-02-14]
- Qualifying Notice for Idhifa [2019-02-11]
- Summary of Cancellation for Innohep Control number 199839 [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Kadcyla [2019-02-11]
- Regulatory Decision Summary for LUTATHERA [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Ofev [2019-02-11]
- Regulatory Decision Summary for ORILISSA [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Tafinlar [2019-02-11]
- Summary basis of decision for Xermelo [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Zepatier [2019-02-11]
- Summary Basis of Decision (SBD) for ALUNBRIG [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Bexsero [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Bosulif [2019-02-11]
- Post-Authorization Activity Table (PAAT) for Cosentyx [2019-02-11]
- Register of Innovative Drugs [2019-02-08]
- Updated Questions and Answers: Prescription Opioids - Sticker and Handout Requirements for Pharmacists and Practitioners [2019-02-07]
- Updated: Validation rules for regulatory transactions provided to Health Canada in the electronic Common Technical Document (eCTD) format [2019-02-07]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-02-05]
- Updated: Validation rules for regulatory transactions provided to Health Canada in the "non-eCTD electronic-only" format [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Adynovate [2019-02-05]
- Post-Authorization Activity Table (PAAT) for BAT [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Breo Ellipta [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Carbaglu [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Constella [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Egrifta [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Esbriet [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Galexos [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Grastofil [2019-02-05]
- Post-Authorization Activity Table (PAAT) for Ibrance [2019-02-05]
- DPD Extracts [2019-02-01]
- Register of Innovative Drugs [2019-02-01]
January
- Updated Register of Certificates of Supplementary Protection and Applications [2019-01-31]
- Scientific Advisory Committee on Respiratory And Allergy Therapies - Record Of Proceedings (SAC-RAT) [2019-01-31]
- Scientific Advisory Committee on Health Products for Women: Nomination Call for Members and Terms of Reference [2019-01-30]
- Notice: Discontinuation of Acknowledgement Letters for Regulatory Activities received by Health Canada [2019-01-30]
- Register of Innovative Drug [2019-01-28]
- Notice of Compliance (NOC) Data Extracts [2019-01-25]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-01-25]
- Release of the Draft Guidance Document: Regulatory Requirements for Drug Identification Numbers (DINs) [2019-01-25]
- Regulatory Decision Summary for ADCETRIS [2019-01-24]
- Post-Authorization Activity Table (PAAT) for Admelog [2019-01-24]
- Summary basis of decision for Aimovig [2019-01-24]
- Regulatory Decision Summary for BELSOMRA [2019-01-24]
- Regulatory Decision Summary for BIOTHRAX [2019-01-24]
- Regulatory Decision Summary for DARZALEX [2019-01-24]
- Regulatory Decision Summary for FOLOTYN [2019-01-24]
- Post-Authorization Activity Table (PAAT) for Kalydeco [2019-01-24]
- Post-Authorization Activity Table (PAAT) for Neupro [2019-01-24]
- Regulatory Decision Summary for TAKHZYRO [2019-01-24]
- Summary Basis of Decision (SBD) for XYDALBA [2019-01-24]
- Post-Authorization Activity Table (PAAT) for Zonovate [2019-01-24]
- Submissions Under Review [2019-01-22]
- Updated List of Drugs for an Urgent Public Health Need [2019-01-22]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-01-18]
- Updated List of Drugs for an Urgent Public Health Need [2019-01-18]
- Notice of Compliance (NOC) Data Extracts [2019-01-18]
- Post-Authorization Activity Table (PAAT) for Tudorza Genuair [2019-01-17]
- Regulatory Decision Summary for XERMELO [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Xofigo [2019-01-17]
- Regulatory Decision Summary for OXYCODONE (*XTAMPZA ER) [2019-01-17]
- Consultation Notice: Health Canada Requests Feedback on Potential Impacts and Uses if Company Names were added to the Generic Submissions Under Review List [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Pheburane [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Plegridy [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Pomalyst [2019-01-17]
- Summary Basis of Decision (SBD) for RAYALDEE [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Shingrix [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Signifor [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Strensiq [2019-01-17]
- Regulatory Decision Summary for SUBLOCADE [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Sylvant [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Tafinlar [2019-01-17]
- Post-Authorization Activity Table (PAAT) for Tecentriq [2019-01-17]
- Regulatory Decision Summary for TRAJENTA [2019-01-17]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-01-16]
- Notice for Consultation - Proposed new regulatory activity types for transactions filed to the Marketed Health Products Directorate (MHPD) [2019-01-15]
- Post-Authorization Activity Table (PAAT) for Fycompa [2019-01-14]
- Regulatory Decision Summary for Gilenya [2019-01-14]
- Summary Basis of Decision (SBD) for Hemlibra [2019-01-14]
- Post-Authorization Activity Table (PAAT) for Idelvion [2019-01-14]
- Regulatory Decision Summary for Invokana [2019-01-14]
- Regulatory Decision Summary for JIVI [2019-01-14]
- Post-Authorization Activity Table (PAAT) for Kevzara [2019-01-14]
- Summary of Cancellation for NUCALA (Control number 212242) [2019-01-14]
- Post-Authorization Activity Table (PAAT) for Obizur [2019-01-14]
- Summary Basis of Decision for Olumiant [2019-01-14]
- Post-Authorization Activity Table (PAAT) for Orfadin [2019-01-14]
- Regulatory Decision Summary for Perjeta [2019-01-14]
- Updated List of Drugs for an Urgent Public Health Need [2019-01-11]
- Notice of Compliance (NOC) Data Extracts [2019-01-11]
- Post-Authorization Activity Table (PAAT) for Afstyla [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Anoro Ellipta [2019-01-10]
- Regulatory Decision Summary for Brineura [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Brivlera [2019-01-10]
- Regulatory Decision Summary for Crysvita [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Dotarem [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Duavive [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Elelyso [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Empliciti [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Entresto [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Esbriet [2019-01-10]
- Post-Authorization Activity Table (PAAT) for Forxiga [2019-01-10]
- Updated Register of Certificates of Supplementary Protection and Applications [2019-01-10]
- Product Monograph Brand Safety Updates - December 2018 [2019-01-10]
- Register of Innovative Drugs [2019-01-07]
- DPD Extracts [2019-01-02]
- Notice of Compliance (NOC) Data Extracts [2019-01-04]
Page details
- Date modified: